65

Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
Rad: 06-043842- -00002-0000
Fec: 2007-01-30 13:30:48 Dep. 2020 NUEVAS CREACIONES
Tra. 11 PATENTES
Eve: 378 PASE NACIONAL
Act 400 OPOSICION SERVICIER Folios: 134

FORMULARIO ÚNICO DE OPOSICIÓN

① OPOSICIÓN A :

- [x] Patente de Invención.
- [ ] Patente de Modelo de Utilidad.
- [ ] Diseño Industrial.
- [ ] Esquema de Trazado para Circuitos Integrados.
- [ ] Marcas de Productos o Servicios.
- [ ] Marca Colectiva.
- [ ] Marca de Certificación.
- [ ] Lema Comercial.

SOLICITUD PUBLICADA

Número del expediente: 06-043842

Solicitante: ALMIRALL PRODESFARMA S.A

Apoderado: CARLOS R. OLARTE

Título de la nueva creación o denominación del signo: "FORMAS DE ADMINISTRACIÓN MASTICABLES, NO COMPRIMIDAS DOSIFICADAS INDIVIDUALMENTE".

Gaceta: 569

③ OPOSICIÓN PRESENTADA POR:

SOLICITANTE	Nombre: PROCAPS S.A Dirección: CALLE 80 No. 78B -201 Nacionalidad o Domicilio: COLOMBIA Lugar de Constitución: BARRANQUILLA Teléfono: (571)3719900 Fax: (571)3730818 E-mail:	**IDENTIFICACIÓN** C.C. [ ] NIT [X] C.E. [ ] Otro [ ] Cual Número 890.106.527-5
REPRESENTANTE O APODERADO	Nombre: LAURA CATALINA SILVA BARRERA Dirección: CARRERA 13 No. 119-95 OF 104 Teléfono: (571)2131213 Fax: (571)6121979 E-mail: negocios@optimum-co.com	**IDENTIFICACIÓN** C.C. [ ] NIT [X] C.E. [ ] Otro [ ] Cual Número 52.455.803 TP 147399

④ FUNDAMENTOS DE LA OPOSICIÓN:

Causal: Art.14, 16, 18, 20 y 30 de la Decisión 486 de la CAN
No cumple con los requisitos de patentabilidad.

Signo opositor:

Justificación:

La presente solicitud no cumple con los requisitos de patentabilidad dado que lo revelado, ya se encontraba en el estado de la técnica o es posible derivarlo de la misma tal y como se demostrará en el capítulo "Fundamento de Hechos".

2000-F04

⑤ **Comprobante de pago No.** _____ **Fecha** _____

60

⑥ **ANEXOS**

- [x] Comprobante de pago de la tasa.
- [x] Poderes, si fuere el caso.
- [x] Pruebas de los fundamentos de la oposición.
- [ ] Documentos que acrediten el legítimo interés, si fuere el caso.
- [x] Documento que acredita la existencia y representación legal de las partes, cuando sean personas jurídicas.

⑦

NOMBRE: LAURA CATALINA SILVA BARRERA

FIRMA: Laura Catalina Silva B

C.C. 52.455.803 **TP.** 147399

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.

Señora Jefe,

DIVISIÓN DE NUEVAS CREACIONES

Superintendencia de Industria y Comercio

E. S. D.

Referencia	**: Expediente N° 06043842**
Asunto	**: Oposición a la solicitud de patente de Invención titulada "FORMAS DE ADMINISTRACIÓN MASTICABLES, NO COMPRIMIDAS DOSIFICADAS INDIVIDUALMENTE.".**
Solicitante	**: ALMIRALL PRODESFARMA S.A.**
Opositora	**:PROCAPS S.A.**

Publicada en la Gaceta de la Propiedad Industrial

N° 569 del 31 de Octubre de 2006

Yo, ***Laura Catalina Silva B*** abogada con tarjeta profesional N° **147399** del consejo superior de la judicatura, en mi condición de apoderada de la sociedad ***PROCAPS S.A.*** conformada bajo las leyes de la República de Colombia y domiciliada en la ciudad de Barranquilla, Colombia, atentamente manifiesto que estando dentro del término de ley y por orden expresa de mi representada, presento oposición a la concesión del registro de la patente de Invención titulada ***"FORMAS DE ADMINISTRACIÓN MASTICABLES, NO COMPRIMIDAS DOSIFICADAS INDIVIDUALMENTE"*** solicitada por la empresa ***ALMIRALL PRODESFARMA S.A.***, y pido a Usted declarar fundada esta oposición y en consecuencia negar el registro de la patente solicitada.

1. INTERÉS PARA ACTUAR

Conforme a lo dispuesto en el artículo 42 de la Decisión 486 de 2000 de la CAN, estando dentro del término estipulado por la ley, manifiesto el legítimo interés de nuestra representada para oponerse al registro de la patente de la referencia, atendiendo a que la solicitud pretendida no cumple con los requisitos dispuestos en la ley como se analizará más adelante y de ser concedida afectaría directamente la comercialización de algunos productos de mi representada, que contienen, en particular en materia de fabricación de cápsulas de gelatina blanda. Por lo tanto, solicito respetuosamente a ese Despacho se sirva tener en cuenta la presente oposición dentro del trámite administrativo que se surte en esta Superintendencia.

2. FUNDAMENTOS DE HECHOS

2.1. La solicitud objeto de la presente fue presentada el 9 de mayo de 2006, reivindicando prioridad bajo las solicitudes ES/P200302612 del 2003-11-10 y fue publicada en Colombia, en la Gaceta de la Propiedad Industrial Nº 569 del 31 de octubre de 2006, página 401, Nº publicación 531 cuya publicación internacional corresponde a la WO2005/048974 del 2005-06-02.

2.2. La solicitud colombiana **06043842** objeto de la presente oposición, se refiere a formas de administración dosificadas individualmente no comprimidas que comprenden una composición de al menos una sustancia farmacéuticamente activa disuelta o dispersada en un material matriz que comprende una mezcla de al menos 0,2% en peso de gelatina, al menos un agente estabilizador y al menos un alcohol

soluble en agua y/o agua como disolvente, siendo dicha composición plástica a temperatura elevada, caracterizadas porque: el agente estabilizador se selecciona del grupo formado por (i) ésteres de la glicerina y ácidos grasos y (ii) Productos originados por la reacción de alcoholisis / esterificación de dichos ésteres de la glicerina y ácidos grasos con polietilenglicoles, y el agente estabilizador tiene un punto de fusión en el intervalo de 42° C a 63° C el agua está presente en una cantidad no superior al 46% en peso de la composición. Adicionalmente, el documento se refiere a formas de administración dosificadas individualmente en las que el estabilizante está presente en una cantidad superior al 1 % en peso de la formulación; donde las formas de administración dosificadas individualmente están envasadas en blisters o cavidades preformadas a partir de láminas; donde las formas de administración comprenden más del 18% en peso de al menos una sustancia farmacéuticamente activa; donde dichas formas de administración dosificadas individualmente comprenden un antiácido; y, donde las formas de administración dosificadas individualmente no comprimidas, comprenden al menos 10% en peso de la composición de al menos un alcohol soluble en agua y/o agua como disolvente.

2.3. En primera instancia, se debe advertir que la reivindicación 21 y 22 se refieren al uso y según la legislación, decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- "*Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento (...)*", los usos no están contemplados como patentables. Solo serán patentables los productos o procedimientos.

2.4.De otra parte el artículo 14 de la Decisión 486 de la CAN consagra lo siguiente: "*Los países miembros otorgarán patentes para las invenciones, sean de producto o*

procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial". Así las cosas, las invenciones objeto de patente deben ser nuevas y tener nivel inventivo. Bien, pues antes de la fecha de prioridad de esta solicitud se encuentran los siguientes documentos que afectan la novedad y el nivel inventivo de la presente solicitud:

- D1: US4761407, 1988-08-02.
- D2: US6060078, 2000-05-09
- D3: WO02064109, 2002-08-22

2.5.Ahora bien, el documento D1, particularmente en el resumen y descripción, particularmente en los ejemplos 7 y 8, se refiere formas orales de solidificación instantánea que comprende al menos 10% por peso de un alcohol soluble en agua y/o agua como solvente (propilene glicol en 10 partes), ketoprofen, glicerol monostearato, menos de 46% de agua y al menos 0,2% por peso de una gelatina. Según dicho documento anterior D1, la composición es mezclada en estado fundido a una temperatura de 50 a 55°C y vertido dentro de un sustrato formado. Al enfriarse, la composición se solidifica. Así las cosas, el documento anterior ya revelada formas no comprimidas que incluyen agentes estabilizadores con un punto de fusión en el intervalo de 50° C a 55° C y donde el agua está presente en una cantidad no superior al 46% en peso de la composición. De esta manera es claro que este documento D1, revela una misma forma de administración dosificada no comprimida. Por lo tanto, a los ojos de este documento D1, la presente solicitud no es novedosa.

2.6.Por su parte, el documento D2, particularmente en el resumen y descripción, revela una forma oral que comprende un fármaco antiácido, gelatina (0,2% por peso) y

gliceril monostearato (p.m.=55°C o más), donde el agua contiene glucosa liquida en una proporción de menos del 46% (ejemplo 3). De igual forma, el documento D3, según su descripción, particularmente en los ejemplos 2 y 14, define una forma que comprende un fármaco, gliceril monostearato SE (p.m. = 54-64°C) o gliceril monostearato (p.m. =55°C o más) y gelatina o glicerogelatina, donde el agua comprende más del 10%, pero menos del 46% por peso. Según dicho documento D3, la composición es mezclada a una temperatura de 90°C en estado fundido para ser depositado en un molde de lámina de aluminio. Así las cosas, una persona versada en la materia, a partir de los documentos D2 y D3, en combinación con el documento D1, pues llegar de manera obvia a la solución propuesta en el capítulo reivindicatorio de una forma no comprimida que incluyen agentes estabilizadores con un punto de fusión en el intervalo de 42° C a 63° C y donde el agua está presente en una cantidad no superior al 46% en peso de la composición. De esta manera es claro que a partir de dichos documentos combinados, D1, D2, y D3, es posible llegar a una misma forma de administración dosificada no comprimida. Por lo tanto, a los ojos de dichos documentos combinados, D1, D2, y D3, la presente solicitud no comprende altura o nivel inventivo.

2.7. En consecuencia y de acuerdo a lo descrito anteriormente, se deriva que la solicitud colombiana **06043842** no puede pretender un monopolio por patente toda vez que lo que pretende no cumple con los tres requisitos necesarios para su protección.

2.8. Que por consiguiente, respecto a la solicitud pretendida se tiene que:

2.8.1. <u>CARECE DE NOVEDAD</u>: Según la decisión 486 de la Comunidad Andina de Naciones, Artículo 16.- *"Una invención se considerará nueva cuando no está comprendida en el estado de la técnica. El estado de la técnica comprenderá todo lo que*

haya sido accesible al público por una descripción escrita u oral, utilización, comercialización o cualquier otro medio antes de la fecha de presentación de la solicitud de patente o, en su caso, de la prioridad reconocida.". A la fecha de prioridad, el 10 de noviembre de 2003, ya era conocido, pues como se demostró, era parte del arte anterior con base en el documento D1, una forma no comprimida que incluyen agentes estabilizadores con un punto de fusión en el intervalo de 50° C a 55° C y donde el agua está presente en una cantidad no superior al 46% en peso de la composición, sobre el cual busca protección en el capítulo reivindicatorio.

2.8.2. <u>CARENCIA DE ALTURA INVENTIVA</u>. Según la Decisión 486 de la Comunidad Andina de Naciones, Artículo 18.- *"Se considerará que una invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica.".* A la fecha de prioridad, 10 de noviembre de 2003, a partir de los documentos D1, D2, y D3 en combinación, es posible deducir una forma de administración dosificada no comprimida según lo definido en las reivindicaciones de la presente solicitud.

2.8.3. <u>CARENCIA DE APLICACIÓN INDUSTRIAL</u> La Decisión 486 de la CAN consagra en su artículo 14 lo siguiente: *"Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial".* La presente solicitud carece de aplicación Industrial ya que como se demostró anteriormente, algunas cláusulas reclaman el uso y estos no son aplicables industrialmente porque primero no se obtiene un producto o proceso; y segundo no es reproducible o repetible a escala industrial. Por lo

tanto, el objeto de la presente invención referido a los usos, no cumplen con el requisito de la aplicación industrial.

2.9. Dado lo anterior, es posible deducir que la solicitud y lo reivindicado no es objeto de patentabilidad pues es contrario a lo que dicta la Decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- *"Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial."*. La solicitud pretendida no cumple con los tres requisitos de patentabilidad.

2.10. Por todo lo anterior, atentamente solicito a usted que se sirva declarar fundada la presente oposición y negar el registro de Patente de invención denominada ***"FORMAS DE ADMINISTRACIÓN MASTICABLES, NO COMPRIMIDAS DOSIFICADAS INDIVIDUALMENTE"*** solicitada por la empresa ***ALMIRALL PRODESFARMA S.A.,*** solicitud Colombiana que apareció publicada en la Gaceta de la Propiedad Industrial N° 569.

3. PRUEBAS

De conformidad con lo dispuesto por las normas vigentes, solicito a usted tener como prueba en este asunto los siguientes:

- D1: US4761407, 1988-08-02.
- D2: US6060078, 2000-05-09
- D3: WO02064109, 2002-08-2

Optimum

Derecho de la Competencia, Propiedad Industrial y Comercio Exterior

4. FUNDAMENTO DE DERECHO

Fundamento esta observación en las normas legales siguientes:

4.1. Numeral 1 del artículo 586 del Código de Comercio.

4.2. Artículo 42 de la Decisión 486 de la Comisión del Acuerdo de Cartagena.

4.3. En las demás normas concordantes.

5. ANEXOS

Para los efectos correspondientes anexo al presente escrito los siguientes documentos:

- D1: US4761407, 1988-08-02.
- D2: US6060078, 2000-05-09
- D3: WO02064109, 2002-08-22

6. NOTIFICACIONES

Para efectos de notificaciones que por disposición del artículo 50 del Decreto 01 de 1984 debe hacer su Despacho, informo que mi representada y la suscrita recibiremos notificaciones en la Secretaría de su Despacho o en mis oficinas situadas en la Transversal 13ª Nº 119-95, Of. 104 de esta ciudad de Bogotá.

Señor Superintendente,

LAURA CATALINA SILVA BARRERA

C.C. 52'455.803 de Bogotá

T.P.A. 147399 del C.S. de la J.

75

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 07 - 8,486
FECHA : ENERO 30 DE 2007

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
Rad: 06-043842 -00002-0000
Fec: 2007-01-30 13:25:48 Dep. 2020 NUE CREACIONES
Tra. 11 PATENTE
Eve: 370 FASE NACIONAL
Act 400 OPOSIOBSERVTER Folios: 134

C O N S I G N A C I O N

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
OTECH LTDA.	CONSIGNACION	BANCO POPULAR	050-00110-6	63773495	30/01/2007	190,000.00
OTECH LTDA.	RECIBO DE CAJA			5088	19/01/2007	533,200.00
OTECH LTDA.	RECIBO DE CAJA			7204	24/01/2007	37,500.00
OTECH LTDA.	RECIBO DE CAJA			99575	28/12/2006	10,000.

C O N C E P T O

CANT.	RENTISTICO		CONCEPTO	TOTAL CONCEPTO
1	50005-01-04	PRESENTACION DE OBSERVACIONES	12 MARCAS Y LEMAS COMERCIALES	256,000.00
			TOTAL : $	256,000.00

ON: DOSCIENTOS CINCUENTA Y SEIS MIL PESOS

RESPONSABLE : ______________________

RECIBO DE CAJA APLICADO AL EXPEDIENTE No.______________________

PROCAPS

20 12

PODER ESPECIAL

Yo, **WALTER TANAKA TATEKAWA**, mayor de edad y vecino de la ciudad de Barranquilla (Colombia), identificado como aparece al pie de mi firma, quien en el presente documento actúa en calidad de Representante Legal de la sociedad **PROCAPS S.A.** sociedad legalmente constituida y domiciliada en la ciudad de Barranquilla (Colombia), por el presente documento otorgo a la doctora **LAURA CATALINA SILVA BARRERA**, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. 147399, poder especial, amplio y suficiente, para formular oposiciones u observaciones a la solicitud de patente No. **06043842**, titulada **"FORMAS DE ADMINISTRACIÓN MASTICABLES, NO COMPRIMIDAS DOSIFICADAS INDIVIDUALMENTE"** de **ALMIRALL PRODESFARMA S.A.**, publicada en la gaceta No. 569 del 31 de Octubre de 2006.

Nuestro apoderado queda facultado, de manera expresa, para realizar todo tipo de actos necesarios para llevar a cabo el trámite de la oposición, incluyendo, sin limitación, preparar y presentar solicitudes, hacer declaraciones, pagar tasas, contribuciones e impuestos, recabar los títulos o certificados. Asimismo quedan autorizados para impugnar administrativa y judicialmente todo lo que fuere resuelto en el expediente a que se hace expresa referencia en el presente poder, con todas las facultades generales y específicas que fuera requerido para ella.

De la misma manera, además de las facultades que le confiere la naturaleza del presente mandato, se encuentran facultados para recibir, desistir, transigir, sustituir, y reasumir el presente poder, incoar acciones, interponer recursos y demás facultades conferidas por la ley.

Dado y Firmado en Barranquilla (Colombia) a los 10 días del mes de enero de 2007.

PROCAPS S.A.
WALTER TANAKA TATEKAWA
C.C. N° 16.251.923 de Palmira
Representante Legal

Acepto:

LAURA CATALINA SILVA BARRERA
C.C. 52'455.803 de Bogotá
T.P.A. 147399 del C.S. de la J.

ADY ISABEL NAMEN SIGURA
NOTARIA SEGUNDA DEL CIRCULO DE BARRANQUILLA
CERTIFICA
Que la(s) firma(s) que aparece(n) en el documento que antecede se asemeja(n) a la(s) de Walter Tanaka Tatekawa
Que aparecen reclamada(s) en esta Notaría previa confrontación de la(s) misma(s).
(Decreto 960/70) Barranquilla 24 de Enero de 2007

REPUBLICA DE COLOMBIA
NOTARIA SEGUNDA
ADY ISABEL NAMEN SIGURA
NOTARIA

DILIGENCIA DE RECONOCIMIENTO

ANTE SR. JUAN ENRIQUE NIÑO GUARIN Notario cuarenta y tres del Circuito de Bogotá, D.C. Compareció:

Laura Catalina Silva Bueno

Identificado con C.C. No. 52455803 de T.P. 147395 C.S.J.

y declaró que reconoce como suya la firma que aparece en el presente documento y que la misma es igual que la huella (índice derecho) impresa en el mismo.

29 ENE. 2007

Fecha:

JUAN ENRIQUE NIÑO GUARIN NOTARIO CUARENTA Y TRES

NOTARIA CUARENTA Y TRES DEL CIRCULO
JUAN ENRIQUE NIÑO GUARIN
NOTARIO CUARENTA Y TRES
BOGOTÁ, D.C.

No. 10757560

95

77

CAMARA DE COMERCIO DE BARRANQUILLA

07**********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

EL SUSCRITO SECRETARIO DE LA CAMARA DE COMERCIO DE BARRANQUILLA,

C E R T I F I C A

Que por Escritura Pública No. 1,190 del 22 de Julio de 1976, ot rgada en la Notaria Tercera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 28 de Julio de 1976 bajo el No. 6,070 del libro respectivo, fue constituida la sociedad----------
limitada denominada "PRODUCTORA DE CAPSULAS DE GELATINAS LIMITADA "PROCAPS LIMITADA".----------

C E R T I F I C A

Que por Escritura Pública No. 1,307 del 28 de Junio de 1979, t rgada en la Notaria Tercera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 23 de Julio de 1979 bajo el No. 10,039 del libro respectivo, la sociedad antes mencionada----------
se transformo en sociedad anonima bajo la denominacion social de "PRODUCTORA DE CAPSULAS DE GELATINA S.A." PROCAPS S.A.".----------

C E R T I F I C A

Que por Escritura Pública No. 3,810 del 31 de Dic/bre de 1980, torgada en la Notaria Primera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 30 de Enero de 1981 bajo el No. 12,705 del libro respectivo, la sociedad antes mencionada----------
se transformo en sociedad de responsabilidad limitada bajo al raz n s cial de "PRODUCTORA DE CAPSULAS DE GELATINA LIMITADA "PROCAPS LI - MITADA".----------

C E R T I F I C A

Que por Escritura Pública No. 3,755 del 10 de Nov/bre de 1983, ot rgada en la Notaria Unica de Soledad, inscrito(as) en esta Cámara de Comercio, el 22 de Nov/bre de 1983 bajo el No. 17,922 del libro respectivo, la sociedad antes mencionada----------
se transformo en sociedad anonima bajo la denominacion social de "PRODUCTORA DE CAPSULAS DE GELATINA S.A. "PROCAPS S.A.".----------

C E R T I F I C A

Que por Escritura Pública No. 3,615 del 06 de Dic/bre de 1996, torgada en la Notaria 2a. de Barranquilla, inscrit (as) en esta Cámara de Comercio, el 20 de Dic/bre de 1996 bajo el No. 67,218 del libro respectivo, la s ciedad antes menci nada----------

********** C O N T I N U A **********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.----------

NIT: 890.106.527-5.

cambio de razon social, por la denominacion LABORATORIOS PROCAPS S.A. ----------

C E R T I F I C A

Que por Escritura Pública No. 3,775 del 18 de Dic/bre de 1996, otorgada en la Notaria 2a. de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 23 de Enero de 1997 bajo el No. 67,704 del libro respectivo, la sociedad antes mencionada----------

cambio de razon social, por la denominacion PROCAPS S.A. ----------

C E R T I F I C A

Que dicha sociedad ha sido reformada por las siguientes escrituras y/o documentos privados:

Numero	aaaa/mm/dd	Notaria	No. Insc o Reg	aaaa/mm/dd
39	1979/01/18	Notaria 3a. de Barranquilla.	9,452	1979/01/24
992	1981/04/30	Notaria 1a. de Barranquilla.	13,112	1981/05/06
1,464	1982/08/27	Notaria Unica de Soledad	15,533	1982/09/08
2,744	1983/08/18	Notaria Unica de Soledad	17,416	1983/08/26
3,826	1984/07/16	Notaria Unica de Soledad	19,554	1984/07/27
3,835	1985/08/26	Notaria Unica de Soledad	22,230	1985/09/04
2,260	1986/09/10	Notaria Unica de Soledad.	24,995	1986/09/15
1,849	1989/07/11	Notaria 2a. de Barranquilla.	33,909	1989/07/13
444	1990/02/21	Notaria 2a. de Barranquilla.	36,101	1990/03/16
3,090	1991/12/17	Notaria 2a. de Barranquilla	43,993	1992/01/28
269	1993/02/01	Notaria 2a. de Barranquilla	48,428	1993/02/16
2,342	1993/07/28	Notaria 2a. de Barranquilla	50,582	1993/08/10
3,652	1993/11/09	Notaria 2a. de Barranquilla	51,798	1993/11/22
3,615	1996/12/06	Notaria 2a. de Barranquilla	67,218	1996/12/20
89	1997/01/16	Notaria 2a. de Barranquilla	67,704	1997/01/23
2,070	1997/07/17	Notaria 2a. de Barranquilla	70,627	1997/07/31
2,281	1997/08/04	Notaria 2a. de Barranquilla	70,813	1997/08/14
765	1999/04/22	Notaria 3a. de Barranquilla	80,628	1999/04/23
459	2001/02/21	Notaria 2a. de Barranquilla	91,502	2001/02/23
2,608	2001/10/05	Notaria 2a. de Barranquilla	95,771	2001/11/08
1,730	2004/07/29	Notaria 2. de Barranquilla	112,999	2004/08/26
416	2005/03/03	Notaria 2. de Barranquilla	116,364	2005/03/10
1,613	2005/07/28	Notaria 2. de Barranquilla	119,322	2005/08/18

C E R T I F I C A

Que de acuerdo con la(s) escritura(s) arriba citada(s), la sociedad se rige por las siguientes disposiciones:

DENOMINACION O RAZON SOCIAL:

PROCAPS S.A.----------

SIGLA: PROCAPS.

DOMICILIO PRINCIPAL: Barranquilla.

NIT No: 890.106.527-5.

MATRICULA MERCANTIL: 24,802.

C E R T I F I C A

********** C O N T I N U A **********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

Direccion para notificaciones judiciales:
CL 80 No 78 B - 201.
De la ciudad de Barranquilla.

C E R T I F I C A

DURACION: El término de duración de la sociedad se fijó hasta el 18 de Agosto de 2073.

C E R T I F I C A

OBJETO SOCIAL: El objeto principal de la sociedad sera: a)-La fabricaci n de capsulas y otros productos similares a partir de materiales tales como gelatinas u otros de distinta naturaleza, que puedan ser utilizados como envases o recipientes de productos y sustancias quimicas, farmaceuticas y cosmeticas, para uso y consumo humano y veterinario; b)-La investigacion, desarrollo y fabricacion de toda clase de productos y sustancias quimicas, farmaceuticas y cosmeticas para uso y consumo humano, animal y vegetal; c)-La compra y venta de materias primas, insumos y productos intermedios necesarios para l s procesos de fabricacion de sustancias quimicas, farmaceuticas,alimen ticias y cosmeticas, asi como la comercializacion interna y externa de l s productos terminados, d) La compra, venta, importacion, exportacion y distribucion de toda clase de elementos instrumentales y equipos medicos,quirurgicos,odontologicos,y hospitalari s para la salud humana y animal. e)La compra,venta,exportacion y disdistribucion de dulces, confites, galletas y todo tipo de g l sinas o alimentos para el consumo humano. f) Actuar como representante o agente de personas naturales y juridicas, naci - naci nales y extranjeras en la realizacion de operaciones o transacci nes relacionadas con la industria farmaceutica y en especial c n cualquiera de las actividades descritas en los literales a), b), c). d) y e) antes descritos; g) Prestar los servici s de ases ria y consultoria en las areas administrativas, de mercade , analisis clinico, asistencia tecnica, investigacion, costos y produccion, exportaciones, importaciones, ventas, relacionadas con iguales o similares actividades a las que constituyen el objeto de PROCAPS S.A., asi como los de publicidad y promocion de product s quimicos, cosmeticos y farmaceuticos para uso humano, animal industrial; h)-Adquirir, operar, administrar y explotar, a cualquier titul , empresa o establecimientos dedicados a la investigacion, desarrollo, fabricacion o comercializacion de productos quimic s, farmaceutic s, hospitalarios o cosmetic s. En desarrollo de su bjet principal, la sociedad podra tomar interes s cial como accionista, s ci fundador de empresas que tengan igual similar objet , com-

********** C O N T I N U A **********

prar, vender, importar y exportar maquinarias, insumos y repuestos requeridos para el desarrollo de sus actividades; tomar dinero en prestamo, financiar y garantizar las operaciones comerciales que celebre con terceros relativas a su objeto; celebrar y ejecutar todo tipo de actos y contratos necesarios para desarrollar sus operaciones; girar, aceptar, otorgar y protestar todo tipo de titulos valores e instrumentos negociables; comprar, vender y constituir gravamenes sobre bienes muebles e inmuebles; designar representantes apoderados en el pais y en el exterior y, en general, realizar cualquier acto o negocio que sea necesario o conveniente para el desarrollo de su objeto social y para la mejor proteccion de sus intereses corporativos o la de sus socios. La sociedad podra garantizar el cumplimiento de obligaciones adquiridas por terceros o por sus socios, para lo cual podra inclusive constituir gravamenes reales s bre sus bienes de cualquier naturaleza.----------

C E R T I F I C A

CAPITAL	Nro Acciones	Valor Acción
Aut rizado		
$**********2,000,000,000	**********2,000,000	**********1,000
Suscrito		
$**********1,220,000,000	**********1,220,000	**********1,000
Pagado		
$**********1,220,000,000	**********1,220,000	**********1,000

C E R T I F I C A

ADMINISTRACION: La direccion y administracion de la sociedad c rresponderа a la Asamblea General de Accionistas, a la Junta Directiva, al Presidente, al Vicepresidente y a un Gerente General. Corresponde a la Junta Directiva las siguientes funciones y atribuciones entre otras: Autorizar cualquier acto o contrato cuya cuantia sea superior al equivalente en pesos Colombianos a doscientos cincuenta mil dolares de los Estados Unidos de America (US$250.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la transacion. Cuando se trate de operaciones en virtud de las cuales la sociedad garantice obligaciones de terceros o de los socios, se requerira que la operacion sea aprobada con el vot de por l menos 2/3 partes de los integrantes de la Junta Directiva.
La sociedad tendra un Presidente , quien ejercera la representacion legal de la sociedad y tendra las siguientes atribuciones entre otras: Ejecutar las decisiones de la Asamblea General de Accionistas y de la Junta Directiva. Ejercer la Representacion Legal de la sociedad en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad c n l previsto en las leyes y en los presentes estatutos. Constituir apoderados judiciales y extrajudiciales, recibir notificaciones, absolver interrogatorios de parte, confesar obligaciones de la sociedad, transigir, disistir y allanar a la sociedad en cualquier asunt judicial. Aprobar y celebrar en nombre de la socieda todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos colombianos a doscientos cincuenta mil dolares de l s

********** C O N T I N U A **********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

Estados Unidos de America (US$250.000), liquidados a la tasa de cambi representativa del mercado vigente el dia en que se surta la transacion o celebracion del acto. Las demas funciones que le c rresponden como Representante Legal por disposicion de la ley, de estos estatutos o de la Junta Directiva. El Presidente tendra un suplente, designado por la Junta Directiva, quien reemplazara al Presidente en sus faltas temporales, absolutas o meramente accidentales, con entidades facultades y sin que sea necesario para ello acreditar la ausencia del principal. La sociedad tendra un Vicepresidente designado por la Junta Directiva, quien tambien ejercera la representacion legal de la sociedad, pudiendo ejercerla conjunta separadamente con el Presidente. El vicepresidente tendra las siguentes facultades entre otras. Ejecutar dentro de su competencia las decisiones de la Asamblea General de Accionistas, de la Junta Directiva y del Presidente. Ejercer la representacion legal de la sociedad en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Constituir apoderados judiciales y extrajudiciales, recibir notificaciones, absolver interrogat rios de parte, confesar obligaciones de la sociedad, transigir, desistir y allanar a la sociedad en cualquier asunto judicial. Aprobar y celebrar en nombre de la sociedad todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos colombianos a cient cincuenta mil dolares de los Estados Unidos de America (US$150.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion o celebracion del acto, siempre que no se trate de enajenar bienes inmuebles o cualquier otro activo fij de la sociedad, inclusive de naturaleza muebles, acciones, cuotas o partes de interes inversiones y todo tipo de derechos de la sociedad, o de constituir gravamenes sobre cualquiera de l s anteriores, facultades que radican exclusiva y privativamente en cabeza del Presidente. Las demas funciones que le corresponda como Representante legal por disposicion de la ley, de estos estatutos o de la Junta Directiva. El Vicepresidente tendra (1) suplente, designado por la Junra Directiva, quien lo reemplazara conjunta separadamente en sus faltas temporales, absolutas o meramente accidentales, con identicas facultades y sin que sea necesari para ell acreditar la ausencia del principal. La sociedad tendra un (1) Gerente General, con su respectivo Suplente, designados por la Junta Directiva. El Suplente reemplazara al Gerente General, en sus faltas temporales, absolutas o meramente accidentales, quien junto con el gerente general, llevaran la representacion legal de la sociedad, c n identicas facultades, pudiendolas ejercer c njunta separadamente c n el Presidente y Vicepresidente, c n identicas facultades que el Gerente General y sin que sea necesari para ello acreditar

********** C O N T I N U A **********

la ausencia del titular. El Gerente General tendra las siguientes facultades entre otras: Ejercer la representacion legal de la s ciedad, en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Aprobar y celebrar en nombre de la sociedad todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos Colombianos a Cincuenta Mil dolares de los Estados Unidos de America (US$50.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion o celebracion del acto, siempre que no se trate de enajenar a cualquier titulo bienes inmuebles o cualquier otro activo fijo de la sociedad, inclusive de naturaleza mueble, acciones, cuotas o partes de interes, inversiones y todo tipo de derechos de la s ciedad de constituir gravamenes sobre cualquiera de las anteri res facultades que radican exclusiva y privativamente en cabeza del Presidente. ----------

C E R T I F I C A

Que según Acta No. 116 del 27 de Junio de 1997 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad:
PROCAPS S.A.----------
cuya parte pertinente se inscribió en esta Cámara de Comercio, el 15 de Agosto de 1997 bajo el No. 70,838 del libro respectivo, y según Acta No. 127 del 22 de Marzo de 2000 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad:
PROCAPS S.A.----------
cuya parte pertinente se inscribió en esta Cámara de Comerci , el 29 de Mayo de 2000 bajo el No. 87,250 del libro respectivo, fueron hechos los siguientes nombramientos:

CLASE: JUNTA DIRECTIVA

Principales

1. Minski Gontovnik Ruben	CC.*******7,463,982
2. Minski Gontovnik Meyer	CC.*******7,461,324
3. Minski Gontovnik Jose	CC.*******8,671,834

Suplentes

1. Minski Zilberblum Elliot	CC.******72,219,541
2. Minski Deitel Daniel	.****************
3. Minski Sharon	PA.*990,212,082,805

C E R T I F I C A

Que según Acta No. 116 del 27 de Junio de 1997 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comerci , el 15 de Agosto de 1997 bajo el No. 70,838 del libro respectivo, fueron hechos los siguientes nombramientos:

Carg /Nombre	Identificación
Presidente.	
Minski Gontovnik Ruben	CC.*******7,463,982

********** C O N T I N U A **********

CAMARA DE COMERCIO DE BARRANQUILLA

07**********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

Suplente del Presidente
Minski Minski Abraham CC.*********802,575
Vicepresidente
Minski Gontovnik Meyer CC.*******7,461,324
Suplente del vicepresidente
Minski Gontovnik Jose CC.*******8,671,834

C E R T I F I C A

Que según Acta No. 11 del 01 de Febrero de 2001 correspondiente a la Junta Directiva en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comerci , el 12 de Febrero de 2001 bajo el No. 91,273 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre Identificación
Gerente General.
Uribe Ochoa Guillermo Luis CC.******70,073,754

C E R T I F I C A

Que según Acta No. 406 del 02 de Sep/bre de 2004 correspondiente a la Junta Directiva en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 09 de Sep/bre de 2004 bajo el No. 113,263 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre Identificación
Suplente del Gerente.
Tanaka Walter CC.******16,251,923

C E R T I F I C A

Que según Acta No. 124 del 29 de Marzo de 1999 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comerci , el 04 de Agosto de 1999 bajo el No. 82,226 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre Identificación
Revis r Fiscal Ppal.
Vargas Pertuz Ana Isabel CC.******32,696,645

C E R T I F I C A

Que según Acta No. 127 del 22 de Marzo de 2000 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comerci ,

********** C O N T I N U A **********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.

NIT: 890.106.527-5.

el 29 de Mayo de 2000 bajo el No. 87,250 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Suplente del Revisor Fiscal.	
Lozada Villareal Milena	CC.******32,748,111

C E R T I F I C A

Que por escritura publica No. 2.608 del 5 de Octubre del 2.001, torgada en la Notaria 2a. de Barranquilla, inscrita en esta Camara de Comercio el 8 de Noviembre del 2.001, bajo los Nos. 95.771, 2.056, 2.057, 2.058, 2.059, 2.060, 2.061, 2.062 y 2.064 del libro respectivo, se reforma totalmente el articulo 65, contenido en la escritura publica No. 3.705 de Noviembre 6 de 1.998, de la Notaria Segunda del Circuito de Barranquilla, y se constituyen los siguientes Apoderados Generales, quienes tendran las funciones que a continuacion se indican en razon de su cargo en la sociedad: 1.-Se c n fiere Poder Especial, Amplio y Suficiente a los senores: WALTER TANAKA TATEKAWA, C.C. No. 16.251.923; WILIIAM ALBERTO BARROS CERRA, C.C. No. 8.715.941, para que cada uno en forma independiente en nombre y representacion de PROCAPS S.A., suscriba todas las declaraci - nes tributarias, aduaneras y cambiarias a que este obligada la s - ciedad, asi como para que responda todo tipo de requerimiento s - licitudes de informacion de las autoridades tributarias, aduaneras o cambiarias,en los ordenes Distrital, Departamental y Nacional. 2.-Se confiere Poder Especial,amplio y suficiente,a los siguientes senores que conforman el Grupo A y el Grupo B para que conjuntamente sus criban contratos de suministros de mercancias y servicios con entidades oficiales, hasta por la suma de US$800.000.oo (OCHOCIENTOS MIL DOLARES DE LOS ESTADOS UNIDOS DE AMERICA), liquidados a la tasa representativa del mercado vigente en el dia que se realice la respectiva transaccion. GUPO A: CLAUDIA TANGARIFE CASTILLO C.C. No. 41.660.293. BRUPO B: WALTER TANAKA TATEKAWA C.C. No. 16.251.923, CARMEN ALICIA FLOREZ C.C. No. 22.434.044, CARMEN ALICIA HERRERA DIAZGRANADOS C.C. No. 22.377.540. Para el ejercicio de estas facultades se requerira por lo menos la firma de uno (1) de los apoderados especiales del Grupo A y uno de los apoderados especiales del Grupo B; 3.-Se otorga Poder General, Amplio y Suficiente a la Doctora JOSEFINA MIELES BUELVAS C.C. No. 33.138.497, a la Doctora MARCELA CARVAJALINO PAGANO C.C. No. 22.579.748, y al D c- t r DANIEL MORENO VILLALBA, C.C. No. 19.113.210; para que cada uno representen a PROCAPS S.A., ante todo tipo de autoridades administrativas y judiciales, en asuntos de naturaleza cambiaria y fiscal, tales como: Contestar e interponer demandas y requerimientos, comparecer en juicios,pedir la practica de pruebas,recibir notificaci - nes,interponer recursos y ejercer acciones contencioso administrativas y de tutela,transigir,conciliar,recibir en nombre de la sociedad desistir, sustituir y reasumir este mandato. Para la celebracion de cualquier acuerdo conciliatorio o transaccional, judicial extrajudicial, cualquiera que sea su cuantia,los Apoderados deberan aportar la autorizacion escrita del Representante Legal de la sociedad. Los Apoderados podran presentar solicitudes de devolucion y/o compensacion de impuestos y recibir los pagos por devoluci nes de

********** C O N T I N U A **********

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

impuestos, firmar, notificarse y realizar todo acto necesario para cumplir con el mandato encomendado.----------

C E R T I F I C A

Que segun documento privado de fecha 7 de junio de 2000, inscrito en esta Camara de Comercio el 8 de junio de 2000, bajo el No.1.786 del libro respectivo, consta que RUBEN MINSKI GONTOVNIK, C.C. No. 7.463.982 de Barranquilla, actuando como Presidente y Representante Legal de la sociedad PROCAPS S.A, confiere poder especial, amplio y suficiente a KAREN FIGUEROA GARCIA, C.C.No.32.732.070 de Barranquilla, para que en su nombre y representacion de la sociedad suscriba todas declaraciones cambiarias a que este obligada PROCAPS S.A, en el giro normal de sus negocios y operaciones sociales.--

C E R T I F I C A

Que segun Documento Privado del 13 de diciembre del 2.002, inscrito en esta Camara de Comercio el 15 de enero del 2.003 bajo el No.2.290 del libro respectivo, el senor RUBEN MINSKI GONTOVNIK, C.C.No.7.463. 982, en calidad de REPRESENTANTE LEGAL, y en condicion de PRESIDENTE de PROCAPS S.A., mediante el presente documento otorgo PODER ESPECIAL al Sr. MARLON TATIS PAREDES, C.C.No.72.176.874, para que en representacion de PROCAPS S.A., suscriba declaraciones, reportes y cualquier tipo de documentos relacionados con tramites o registros de Comercio Exterior ante el Ministerio de Comercio Exteri r y/ cualquier entidad del Estado que haga sus veces. En consecuencia, el Sr. MARLON TATIS PAREDES, podra suscribir en representacion de PROCAPS S.A. declaraciones, reportes y cualquier tipo de document s relacionados con tramites o registros de Comercio Exterior ante el Ministerio de Comercio Exterior y/o cualquier entidad del Estado que haga sus veces.----------

C E R T I F I C A

Que segun documento privado del 10 de noviembre del 2004, inscrito en esta Camara de Comercio el 1 de diciembre del 2.004, bajo el No. 2.753 del libro respectivo consta que RUBEN MINSNSKI GONTOVNIK, C.C. 7.463.982 de Barranquilla, actuando como Presidente y Representante Legal de la sociedad PROCAPS S.A, confiere poder especial, amplio y suficiente a ANTONIO VARELA DIAZ, C.C.No.72.004.669 de Barranquilla, para que en nombre y representacion de la sociedad firme las declaraci nes cambiarias a que este bligada PROCAPS S.A., a suscribrir en el giro normal de sus negoci s y operaci nes s ciales. Por l anteri r, el senor ANTONIO VARELA DIAZ, queda facultado

********** C O N T I N U A **********

PROCAPS S.A.----------
NIT: 890.106.527-5.

para firmar las declaraciones comabiarias y demas documentos relacionados con las declaraciones, notificaciones, aportar y solicitar las pruebas que sean necesarias, desistir en general a realizar t d acto necesario de tal forma que pueda cumplir con el mandato dado.-

C E R T I F I C A

Que segun documento privado del 22 de Febrero de 2005, inscrit en esta Camara de Comercio el 28 de Marzo de 2.005, bajo el No. 2.820 del libro respectivo, consta que WALTER TANAKA TATEKAWA C.C. 16.251-923 de Palmira, quien actua como representante legal de la sociedad PROCAPS S.A, otorga Poder Especial, Amplio y Suficiente al senor MARLON TATIS PAREDES C.C. No. 72.176.874, para que en representaci n de PROCAPS S.A., suscriba declaraciones aduaneras, reportes y cualquier tipo de documentos relacionados con los tramites o registros de comercio exterior ante la direccion de impuestos y aduanas naci - nales y/o cualquier entidad que haga sus veces, y para que responda todo tipo de requerimientos y/o solicitudes de informacion de las autoridades aduaneras en los ordenes distrital, departamental y nacional.----------

C E R T I F I C A

Que por Escritura Pública No. 2,011 del 10 de Octubre de 2006, torgada en la Notaria 2 a. de Barranquilla cuya parte pertinente se inscribió en esta Cámara de Comercio, el 15 de Dic/bre de 2006 baj el No. 3,183 del libro respectivo,----------
Consta que RUBEN MINSKI GONTOVNIK CC.No.7.463.928, quien manifesto que en su condicion de Presidente y Representante Legal de la ------ s ciedad PROCAPS S.A.,confiere poder especial amplio y suficiente a los siguientes senores que conforman el Grupo A y el Grupo B, para que conjuntamente suscriban contratos de suministro de mercancias y servicios con entidades oficiales, hasta por la suma de ochocient s mil dolares de los Estados Unididos de America (US$800.000.00), ---- liquidados a la tasa representativa del mercado vigente en el dia que se realice la respectiva transaccion. Grupo A: IVAN VILLARRAL CAMACHO CC.No.91.201.749. FERNANDO RINCON RIVERA CC.No.79.484.187. CLAUDIA TANGARIFE CASTILLO CC.No.41.660.293.Grupo B. WALTER TANAKA TATEKAWA CC.No.16.251.923. CARMEN ALICIA FLOREZ DE LA ROTA --------- CC.No.22.434.044. RICARDO DORADO HURTADO CC.No.79.715.772.----------

C E R T I F I C A

Que en esta Cámara de Comercio no aparecen inscripciones posteri res de documentos referentes a reforma, disolución, liquidación nombramientos de representantes legales de la expresada sociedad.

C E R T I F I C A

Que su última Renovación fue el: 29 de Marzo de 2006.

La información sobre embargos de establecimiento se suministra en Certificados de Matrícula, la de contratos sujetos a registro, en

********** C O N T I N U A **********

No. 10757565

18
82

CAMARA DE COMERCIO
DE BARRANQUILLA

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.
PROCAPS S.A.----------
NIT: 890.106.527-5.

Certificados Especiales.

ANEXO 1

United States Patent [19]

Campan et al.

[11] **Patent Number: 4,761,407**

[45] **Date of Patent: Aug. 2, 1988**

[54] **SOLID GALENICAL FORM FOR ORAL ADMINISTRATION, AND THE PROCESS FOR ITS PREPARATION**

[75] Inventors: **Jean-Jacques Campan, Courbevoie; Roberto Lombardi, Chatou, both of France**

[73] Assignee: **Rhone-Poulenc Sante, Courbevoie, France**

[21] Appl. No.: **789,365**

[22] Filed: **Oct. 22, 1985**

Related U.S. Application Data

[63] **Continuation of Ser. No. 436,683, Oct. 26, 1982, abandoned.**

[30] **Foreign Application Priority Data**

Oct. 26, 1981 [FR] France 81 20048

[51] **Int. Cl.[4] A61K 31/57; A61K 31/19; A61K 9/22**

[52] **U.S. Cl. 514/179; 514/557; 514/772; 514/774; 514/784; 514/785; 514/948; 514/960**

[58] **Field of Search 514/772, 774, 784, 785, 514/948, 960, 179, 557; 424/16**

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,265,629	8/1966	Jensen	424/16
3,439,089	4/1969	Clarkin et al.	424/78
4,102,806	7/1978	Kondo et al.	424/38

Primary Examiner—J. R. Brown
Assistant Examiner—Jacqueline M. Stone
Attorney, Agent, or Firm—Stevens, Davis, Miller & Mosher

[57] **ABSTRACT**

New solid galenical form for oral administration, consisting of a mixture of one or more active products and two or more excipients which can be liquefied at a temperature compatible with the active product or products, and which are solid at ambient temperature.

3 Claims, No Drawings

SOLID GALENICAL FORM FOR ORAL ADMINISTRATION, AND THE PROCESS FOR ITS PREPARATION

This application is a continuation of application Ser. No. 436,683, filed 10/26/82.

The present invention relates to a new solid galenical form for oral administration and to the process for its preparation.

The known solid pharmaceutical forms for oral administration, containing a unit dose of one or more active principles, are mainly tablets, coated tablets or the like, and gelatine capsules. Although industry has mastered the preparation of such formulations, it is nevertheless true that the processes used, in particular for the manufacture of tablets, are long and complicated and they involve virtually unavoidable losses. For example, the process for the manufacture of tablets is essentially a batch process which must proceed via, in general, 5 to 10 intermediate stages, each of which has to be rigorously controlled. Thus, the overall process can last 1 to 2 weeks. At each intermediate stage, there are unavoidable losses which it is very difficult to reduce. It must also be noted that the multiplicity of manufacturing stages results in a multiplicity of production installations, the effect of which is to make it more difficult to observe good manufacturing practices (emission of dust, contact between the operator and the product, and the like).

Furthermore, tablets are manufactured essentially by mixing powders of different bulk density and different particle size, which makes it more difficult to obtain really uniform doses of the active principle in each tablet and hence to obtain perfectly homogeneous batches of tablets, which constitutes a major disadvantage in the case of active principles used at very low doses.

A new solid galenical form, hereafter referred to as an "instantaneous solidified oral form" or "ISOF", has now been found which has the advantage, over the forms known hitherto, that it can be prepared more rapidly by a continuous process and that it leads to batches of unit doses in which the active principle is distributed very uniformly, even in the case of low doses; it is this new solid galenical form which constitutes one of the subjects of the present invention.

According to the invention, the "ISOF" consists of one or more active principles dissolved or dispersed in two or more excipients which can be liquefied at a temperature above ambient temperature, e.g. 35° C., but below a temperature at which the active principle or principles would be adversely affected, which are compatible with the active principle or principles and are solid at ambient temperature, and which can release the active principle or principles in water or a physiological liquid. It is to be understood that the expression "galenical form" as used in this specification and the accompanying claims denotes pharmaceutical or veterinary compositions generally and is not limited to compositions containing one or several organic ingredients as contrasted with pure chemical substances.

In the galenical form according to the invention, the active principle is dispersed in the form of particles which are generally much finer than in the customary solid oral galenical forms or, preferably, dissolved. This principally results in a change in the bioavailability of the active principle, which is expressed in the release and/or absorption of the active principle and consequently in the metabolism.

The "ISOFs" according to the invention must correspond to precise physical characteristics, which depend mainly on the active principle and its dosage. The essential general characteristics of the "ISOFs" relate to their appearance, their form, their hardness, their weight, their disaggregation and dispersion times and the storage temperature.

The appearance of the "ISOFs" must be homogeneous on the surface and within the compositions, and their surface must be level and smooth.

The forms of the "ISOFs" can vary extremely widely, but their geometry must be compatible with easy mould release and with the method of administration.

The consistency of the "ISOFs" can vary. In general, it must be such that the "ISOF" withstands handling by the user or withstands impacts, e.g. being dropped 1 meter from the ground. Furthermore, their cohesion must be such that they can be removed from their container without harm to their physical integrity.

The weight of the "ISOFs" can be between a few tens of milligrams and several hundred milligrams, the lower limit depending on the precision of the measurement of the amount of "ISOF" in the container, and the upper limit being related to the maximum size of the "ISOF" which can be taken by the patient.

The disaggregation and dispersion time of the "ISOF" is preferably less than 45 minutes in water or an artificial physiological liquid at 37±2° C., with periodic stirring.

The "ISOF" must remain in the solid form during storage, i.e. generally at a temperature below 30° C. However, the m.p. of the composition, which depends on the stability of the active principle, can be considerably higher.

According to the invention, there is a general process for the preparation of "ISOFs", but it must be adapted to suit each particular case, taking into account the specific properties of the active principles used.

A generally preferred process for the preparation of "ISOFs" can be summarised as follows:

1—starting from primary excipients, i.e. substances normally used in galenical pharmacy and listed in the pharmacopoeias, chosen according to their ability to solubilise or disperse the active principles in question, a secondary excipient ($SE_1°$) is prepared which is capable of forming a phase of lipophilic, hydrophilic or amphoteric character, depending on the nature and the properties of the active principles,

2—the active principle is solubilised or dispersed in the secondary excipient $SE_1°$, if appropriate in the presence of a primary excipient assisting its solubilisation or dispersion, to give a phase $\phi 1$, which is kept liquid at a sufficiently high temperature,

3—starting from primary excipients, a secondary excipient ($SE_2°$) is prepared which is of hydrophilic, lipophilic or amphoteric character, depending on the nature of the secondary excipient $SE_1°$, and which forms a phase $\phi 2$, which is kept liquid at a sufficiently high temperature, it being understood that if $SE_1°$ is lipophilic, $SE_2°$ is hydrophilic or amphoteric, if $SE_1°$ is hydrophilic, $SE_2°$ is lipophilic or amphoteric, and if $SE_1°$ is amphoteric, $SE_2°$ is lipophilic, hydrophilic or amphoteric,

4—the phase $\phi 1$ (or $\phi 2$) is then dispersed in the phase $\phi 2$ (or $\phi 1$) at the same temperature, to give a mixture $\phi 3$

of homogeneous consistency, which is liquid at a temperature above the ambient storage temperature,

5—after the phase $\phi 3$ has cooled to a temperature near the solidification temperature, it is poured into suitable containers to give unit "ISOFs", which solidify on cooling, acquiring the cohesion necessary for their subsequent handling, and

6—the container in which the "ISOFs" are present is closed by any suitable means, e.g. by heat-sealing or extrusion.

In general, the whole of the process is carried out without taking any particular precautions as regards the ambient temperature and the relative humidity.

Non-ionic and/or amphoteric surface-active agents, terpenes, aminoacids, polypeptides, alcohols and fatty acids, optionally esterified, polyols, and mixtures thereof are generally used to manufacture the "ISOFs".

Amongst the primary excipients which are particularly suitable, there may be mentioned cetyl alcohol, linoleic acid, isopropyl myristate, glycerol monostearate, gelatine, lecithin, leucine, lysine, glycerophosphoric acid, propylene glycol, glycerol, water, alcohol, and terpenes, such as cineol, menthol, eucalyptol or camphor, this list not implying a limitation.

It is important to point out that the excipients suitable for manufacturing the "ISOFs" cannot be used to manufacture suppositories or "LYOCS". Conversely, the excipients used for these forms of administration, such as triglycerides, polyethylene glycols or lactose, are not suitable for manufacturing the "ISOFs".

It is particularly advantageous to choose the proportions of the various excipients so as to obtain eutectic mixtures, i.e. mixtures of excipients capable of giving molten or liquefied systems at temperatures below the m.p. of each of the constituents, for the purpose of avoiding possible degradation of the active principle or principles.

To carry out the process according to the invention, it can be advantageous to prepare reference secondary excipients which can be modified according to the specific properties of the active principles to be formulated. Taking account of the known characteristics of an active product, it will be possible to choose the type of secondary excipient which permits the most appropriate formulation.

The essential physico-chemical properties which are taken into consideration when choosing the secondary excipient are the solubility, the m.p., the lipophilic, hydrophilic or amphoteric character and the stability as a function of the temperature, but other properties, such as the crystalline form, may be involved. The secondary excipient SE_1' will therefore be chosen so that the dissolution or dispersion of the active principle is carried out at as low a temperature as possible. The active principle dissolved or dispersion in the secondary excipient SE_1' forms the phase $\phi 1$. In the large majority of cases, the phase $\phi 1$ thus obtained cannot be poured directly to form the "ISOF" because either its solubility in water or artificial physiological liquids is virtually zero or too low, after solidification, or it forms a liquid phase which cannot be solidified at ambient temperature. It is therefore necessary to complement the phase $\phi 1$ with a phase $\phi 2$, consisting of a secondary excipient SE_2' which constitutes a carrier capable of keeping the phase $\phi 1$ in the liquid state at a temperature generally above 35° C., and of leading to solidification at ambient temperature so as to form the "ISOF", which will be soluble or dispersible in water or natural or artificial physiological liquids.

Furthermore, it may be necessary to add, to the phase $\phi 1$ or $\phi 2$, primary excipients capable of fixing the volatile constituents, such as certain terpenes.

According to the present invention, the final form in which the medicament is presented is preferably obtained by laying a flexible and tearable foil, in a known manner, over the containers in which the unit "ISOFs" are present. The flexible and tearable foil must be compatible with the "ISOF". It can consist of a thin foil of aluminium or one of its alloys. Preferably, the new pharmaceutical form is packaged in blister packs.

The "ISOFs" according to the present invention are particularly useful for the preparation of unit doses containing a low dose of active product (corticoids, antihistamines, liposoluble vitamins, and the like) or a sensitive product, such as an aminoacid (methionine, cysteine, cystine), a protein or an enzyme (pancreatin, trypsin and the like).

By appropriate choice of the excipients, the "ISOFs" according to the present invention can be used for the formulation of active principles whose release in the organism must be controlled and gradual over a period of time.

The examples which follow, which are given without implying a limitation, show how the invention can be put into practice. The proportions of the various constituents are expressed by weight.

A—Preparation of blank "ISOFs", i.e. "ISOFs" without active product

EXAMPLE 1

Preparation of a blank "ISOF" of lipophilic character

A mixture of water (3 parts), ethanol (6 parts), propylene glycol (5 parts) and lecithin (5 parts) is prepared at a temperature of the order of 20° C., with slow stirring, to give a phase $\phi 2$.

Linoleic acid (5 parts) and isopropyl myristate (2 parts) are added to cetyl alcohol (70 parts) molten at 50° C. A solution obtained by successively dissolving menthol (0.25 part), eucalyptol (0.5 part) and camphor (0.25 part) in cineol (3 parts), at a temperature of the order of 20° C., is added to the resulting solution. This gives a phase $\phi 1$.

The phase $\phi 1$ is added to the phase $\phi 2$, with slow stirring, at a temperature of between 45° and 50° C.

This gives a homogeneous solution of an excipient having a lipophilic character.

EXAMPLE 2

Preparation of a blank "ISOF" of lipophilic character

A phase $\phi 2$ is obtained by melting glycerol monostearate (80 parts).

A mixture consisting of lecithin (1 part), glycerophosphoric acid (1 part) and propylene glycol (1 part) is prepared at a temperature of between 45° and 50° C. A solution obtained by dissolving cineol (5 parts) and eucalyptol (5 parts) in 95° strength alcohol (7 parts), is added to the resulting solution at a temperature of between 50° and 55° C. This gives a phase $\phi 1$, which is added to the phase $\phi 2$, with slow stirring, at a temperature of between 50° and 55° C. This gives a homogeneous solution of an excipient having a lipophilic character.

EXAMPLE 3

Preparation of a blank "ISOF" of lipophilic character

A mixture of 95° strength alcohol (1 part), cineol (1 part), menthol (1 part), eucalyptol (1 part) and camphor (1 part) is prepared, with slow stirring, at a temperature of 20° C., and lecithin (7 parts), heated to a temperature of between 35° and 40° C., is added thereto to give a phase $\phi 1$.

A mixture of isopropyl myristate (85 parts), cetyl alcohol (1 part), linoleic acid (1 part) and glycerol monostearate (1 part) is prepared, with slow stirring, at the same temperature, to give a phase $\phi 2$.

The phase $\phi 1$ is added to the phase $\phi 2$, with stirring, at the same temperature (40° C.). This gives a homogeneous solution of an excipient having a lipophilic character.

EXAMPLE 4

Preparation of a blank "ISOF" of hydrophilic character

A mixture of water (60 parts), gelatine (5 parts), lecithin (1 part) and propylene glycol (5 parts) is prepared, with slow stirring, at a temperature of 50° C., to give a phase $\phi 1$.

A mixture of 95° strength alcohol (10 parts), cineol (3 parts), menthol (0.5 part), eucalyptol (5 parts), camphor (0.5 part) and isopropyl myristate (1 part) is prepared, with slow stirring, at the same temperature, to give a phase $\phi 2$.

The phase $\phi 2$ is added to the phase $\phi 1$, with stirring, at the same temperature (50° C.). This gives a homogeneous solution of an excipient having a hydrophilic character.

EXAMPLE 5

Preparation of a blank "ISOF" of hydrophilic character

A mixture of water (75.5 parts), gelatine (5 parts), lecithin (2 parts), lysine (0.5 part), leucine (0.5 part) and propylene glycol (5 parts) is prepared, with slow stirring, at a temperature of 50° C., to give a phase $\phi 1$.

A mixture of 95° strength alcohol (5 parts), cineol (5 parts), menthol (0.5 part), eucalyptol (0.5 part) and camphor (0.5 part) is prepared, with slow stirring, at the same temperature (50° C.), to give a phase $\phi 2$.

The phase $\phi 2$ is added to the phase $\phi 1$, with stirring, at the same temperature. This gives a homogeneous solution having a hydrophilic character.

EXAMPLE 6

Preparation of a blank "ISOF" of amphoteric character

Glycerol monostearate (1 part) is melted at a temperature of between 55° and 60° C. and a mixture of cetyl alcohol (20 parts) and isopropyl myristate (1 part) is added, with slow stirring, at 55°–60° C., to give a phase $\phi 2$.

A mixture of water (20 parts), gelatine (1 part), lecithin (5 parts), lysine (1 part), leucine (1 part), propanetriol (10.5 parts) and propylene glycol (10.5 parts) is prepared, with slow stirring, at a temperature of 45° to 50° C., and a mixture of 95° strength alcohol (25 parts), cineol (3 parts), menthol (0.25 part), eucalyptol (0.5 part) and camphor (0.25 part), at the same temperature, is added thereto to give a phase $\phi 1$.

The phases $\phi 1$ and $\phi 2$ are heated to a temperature of between 40° and 50° C. and the phase $\phi 1$ is then added to the phase $\phi 2$ at the same temperature, with stirring. This gives a homogeneous solution having an amphoteric character.

B—Preparation of "ISOFs" containing an active product

EXAMPLE 7

"ISOFs" containing 150 mg of ketoprofen for a total weight of 1,000 mg are prepared.

A mixture of 95° strength alcohol (2 parts), propylene glycol (10 parts), menthol (0.5 part) and eucalyptol (15 parts) is prepared, with slow stirring, at a temperature of between 60° and 65° C., and ketoprofen (15 parts) and glycerol monostearate (0.1 part) are added thereto. This gives a phase $\phi 1$.

A mixture of water (37.4 parts), gelatine (18 parts) and lecithin (2 parts) is prepared at the same temperature. This gives a phase $\phi 2$. The phase $\phi 1$ is added to the phase $\phi 2$, at the same temperature, so as to give a homogeneous mixture.

This mixture is poured onto a cellular sheet so that each cell contains 1,000 mg of the mixture. After cooling, whitish rigid "ISOFs" are obtained which have a slight terpene taste and the characteristic smell of the volatile terpenes used.

A unit "ISOF" obtained in this way has a disaggregation and dispersion time of less than 20 minutes in water at 37±2° C.

EXAMPLE 8

"ISOFs" containing 100 mg of ketoprofen for a total weight of 1,000 mg are prepared.

A mixture of 95° strength alcohol (2 parts) and propylene glycol (10 parts) is prepared, with slow stirring, at about 20° C.; it is heated to a temperature of between 60° and 65° C. and a mixture of eucalyptol (15 parts), menthol (0.5 part) and propanetriol (5 parts) is added thereto. A mixture of ketoprofen (10 parts) and glycerol monostearate (0.2 part) is added to the mixture thus obtained, at a temperature of between 60° and 65° C. This gives a phase $\phi 1$.

A mixture of water (37.3 parts), gelatine (18 parts) and lecithin (2 parts) is prepared at a temperature of between 60° and 65° C. This gives a phase $\phi 2$.

The phase $\phi 1$ is added to the phase $\phi 2$, at a temperature of between 60° and 65° C., so as to give a homogeneous mixture.

This mixture is poured onto a cellular sheet so that each cell contains 1,000 mg of the mixture. After cooling, whitish "ISOFs" of soft consistency are obtained which have a slight terpene taste and the characteristic smell of the volatile terpenes used.

A unit "ISOF" obtained in this way has a disaggregation and dispersion time of less than 5 minutes in water at a temperature of 37±2° C.

EXAMPLE 9

"ISOFs" containing 150 mg of ketoprofen for a total weight of 1,000 mg are prepared.

A mixture of eucalyptol (20 parts), menthol (0.5 part), camphor (0.5 part) and alcohol (2 parts) is prepared, with slow stirring, at a temperature of about 20° C., to give a secondary excipient SE_1°; this is heated to a temperature of between 50° and 55° C. and ketoprofen (15 parts) is added thereto. This gives a homogeneous liquid phase $\phi 1$.

A mixture of water (36 parts), gelatine (10 parts), lecithin (3 parts), glycerol monostearate (0.5 part),

ANEXO 2

US006060078A

United States Patent [19]

Lee

[11] Patent Number: 6,060,078

[45] Date of Patent: May 9, 2000

[54] **CHEWABLE TABLET AND PROCESS FOR PREPARATION THEREOF**

[75] Inventor: **Young Won Lee**, Seoul, Rep. of Korea

[73] Assignee: **Sae Han Pharm Co., Ltd.**, Kyunggi-do, Rep. of Korea

[21] Appl. No.: **09/161,904**

[22] Filed: **Sep. 28, 1998**

[51] **Int. Cl.**[7] **A61K 9/20; A61K 9/28**

[52] **U.S. Cl.** **424/440**; 424/439; 424/441; 424/475; 424/481; 514/777; 514/782; 514/784; 514/774; 514/785

[58] **Field of Search** 424/440, 441, 424/439, 464, 465, 474, 475, 481

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,260,596	4/1981	Mackles	424/14
4,271,142	6/1981	Puglia et al.	424/14
4,372,942	2/1983	Cimiluca	424/16
4,423,086	12/1983	Devos et al.	427/3
4,511,553	4/1985	Boesig	424/35
5,460,825	10/1995	Roche et al.	424/470
5,753,255	5/1998	Chavkin et al.	424/441

Primary Examiner—James M. Spear
Attorney, Agent, or Firm—Bachman & LaPointe, P.C.

[57] **ABSTRACT**

The present invention relates to a chewable tablet containing a medicament in a core and a process for preparation thereof. In particular, the present invention relates to a chewable tablet comprising a core containing a medicament in the center of the tablet in a state of jelly or chewable base and an outer layer wrapping the core which is made up of chewable base such as a gum, a soft candy or a caramel. The chewable tablet is easy to take and has a good taste and nice chewing property due to the unique tablet form. In addition, the tablet has an advantage in bioavailability resulting from increased absorption rate and excellent stability due to unique preparation process. Therefore, the chewable tablet and the preparation process of the present invention can be used in pharmaceutical industry usefully.

11 Claims, 1 Drawing Sheet



FIG. 1



FIG. 2

CHEWABLE TABLET AND PROCESS FOR PREPARATION THEREOF

FIELD OF THE INVENTION

The present invention relates to a chewable tablet containing a medicament in a core and a process for preparation thereof. In particular, the present invention relates to a chewable tablet comprising a core containing a medicament in the center of the tablet in a state of jelly or chewable base; and an outer layer wrapping the core which is made up of chewable base such as a gum, a soft candy or a caramel.

BACKGROUND OF THE INVENTION

A tablet, which has been formed by compressing a mixture of medicament and forming agent, is inconvenient to take because it must be swallowed or chewed, and troublesome especially to an aged person.

Soft tablet having good chewing property was developed, in which excipients for chewing property, elasticity and good taste were added to the medicament (Korean Patent application No. 94-2298). But, this tablet had a problem in that the medicament, an effective ingredient, was transformed in physico-chemical properties because the tablet was prepared in such severe condition as the tablet was made in a state of soft candy or jelly by mixing a medicament and forming agents and melting them at high temperatures. That is, temperature condition higher than 90° C. was required for mixing ingredients of the tablet, thus if a medicament was unstable to heat, its properties were liable to transform or the medicament itself was evaporated, which caused to deteriorate the effect of a medicament.

In addition, the conventional chewable tablet has problems to take because of sandy taste in granular chew and chalky taste in mouth.

The present inventors have successfully developed a new chewable tablet comprising a core containing a medicament in the center of the tablet in a state of jelly or chewable base; and an outer layer wrapping the core which is made up of chewable base such as a gum, a soft candy or a caramel. The tablet is easy to take and can keep the stability of a medicament. In addition, a medicament contained in the tablet can be absorbed more rapidly than that of conventional tablet.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a chewable tablet that is easy to take and has a good taste and nice chewing property, and also can be useful in pharmaceutical field taking advantage of keeping the stability of a medicament and increasing bioavailability.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a partially sectional perspective view of a candy rope comprising a core containing a medicament in a state of jelly or chewable base; and an outer layer wrapping the core which is made up of chewable base.

FIG. 2 is a partially sectional perspective view of a chewable tablet of the present invention made by using the candy rope of FIG. 1.

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, a chewable tablet containing a medicament in a core in a state of jelly or chewable base and a process for preparation thereof are provided.

In detail, the tablet of the present invention comprises a core containing a medicament in a state of jelly or chewable base; and an outer layer of chewable base wrapping the core.

Any kind of medicament may be contained in the core, preferably a medicament of bitter taste, a medicament which is unstable to heat, vitamins which are liable to transform, natural plant extracts or other organic compounds may be contained in the core.

More preferably, vitamins such as vitamin A, vitamin B, vitamin B_1, vitamin B_2, vitamin B_6, vitamin C, vitamin E and vitamin K; natural plant extracts such as Sohgunjung-tang extracts, Sipchundaebo-tang extracts and *Eleutherococcus senticosus* extracts; organic compounds such as dimenhydrinate, meclazine.HCl, acetaminophen, asprin, phenylpropanolamine.HCl and cetylpyridinium chloride; or gastrointestinal agents such as aluminum hydroxide gel dried, domperidone, soluble azulene, L-glutamine and hydrotalcite may be contained in the core.

These medicaments may be used alone or in combination. The medicament contained in the tablet may be used in usual dose.

For example, *Eleutherococcus senticosus* extracts is used in the chewable tablet in a dose of 195–390 mg/day; dimenhydrinate in a dose of 20–200 mg/day; meclazine.HCl in a dose of 25–75 mg/day; aspirin in a dose of 1–4.5 mg/day; phenylpropanolamine-HCl in a dose of 75–100 mg/day; cetylpyridinium chloride in a dose of 6–8 mg/day; and domperidone in a dose of 30–60 mg/day.

The jelly base of the core, which contains the above medicament in a state of jelly, may be selected from the group consisting of pectin, sorbitol, maltitol, isomalt, liquid glucose, sugar, citric acid and a flavoring agent.

The chewable base of the core or the outer layer may be selected from the group of gum, soft gum, soft nougat, soft candy, hard candy and caramel, which are easy to take and tasty. In addition, the chewable base may additionally contain excipients selected from the group consisting of sugars; a protecting agent of adhesion to oral cavity and crystallization of sugars; an enhancing agent of chewing property; a keeping agent of hardness and extension property; a flavoring agent; a souring agent; a coloring agent; and combinations thereof, according to the kind of chewable base.

The sugar used in the present invention may be selected from the group consisting of white sugar, liquid glucose, sorbitol, dextrose, isomalt, liquid maltitol, aspartame and lactose, and this sugar may comprise 50–90 weight % by total weight of the ingredients.

Glycerin, lecithin, hydrogenated palm oil or glyceryl monostearate may be used as a protecting agent of crystallization of the sugars in 0.04–2.0 weight % by total weight of the ingredients, to prevent adhesion to oral cavity and improve the soft property of the products.

Isomalt or liquid maltitol may be used as an enhancing agent of chewing property, which can increase the chewing properties by controlling the composition ratio and it must be prepared at temperatures of 135–140° C. under vapor pressure of 5.5 bar.

A gum such as gelatin or arabic gum may be used as a keeping agent of hardness and extension property in 0.1–2.0 weight % by total weight of the ingredients.

In addition, a flavoring agent such as a food flavor or a fruits extract; a souring agent such as citric acid may be added in adequate amount, and a coloring agent such as a food color may be optionally added in small amount.

The chewable tablet of the present invention is prepared by the process in which the medicament, an effective

ingredient, is contained in the core in a state of jelly or chewable base separate from the outer layer, whereas the conventional chewable tablet was prepared by mixing a medicament and additives and then, melting them at high temperatures, therefore, forming soft candy or jelly, in which the medicament was dispersed on the whole tablet.

In detail, the chewable tablet of the present invention is prepared by the following process comprising the steps of:

(a) preparing an outer layer of chewable base and a core of jelly or chewable base, respectively;

(b) mixing a medicament with the jelly or chewable base of the core at room temperature (25° C.);

(c) making candy rope containing fixed amount of medicament (FIG. 1) through the process in which each of the prepared outer layer of chewable base and the core of jelly or chewable base containing medicament is put into two extruding machine, which is designed specially by the present inventors (Korean Patent application No. 98-30511), respectively, and then each of the outer layer and the core is extruded at the same time by using the above extruding machine, maintaining temperatures of 50–90° C. on the outer layer and 5–8° C. on the core; and

(d) forming a chewable tablet by cutting the above candy rope (FIG. 2).

The chewable tablet prepared by the above process has an advantage in bioavailability resulting from increased absorption rate, because the tablet is dissolved or chewed in the mouth and then moved into gastrointestinal tract in a state of whole solution or granule, whereas the conventional solid tablet or capsule was absorbed through disintegration and dissolution.

Further, the conventional chewable tablet was prepared by mixing a medicament, an effective ingredient, and additives, then melting them at high temperatures as a whole, thus the medicament was liable to change in physico-chemical properties. On the contrary, the medicament contained in the chewable tablet of the present invention as an effective ingredient is not changed in physico-chemical properties and keeps the effect of medicament, therefore has a excellent stability, because the chewable tablet of the present invention is prepared by the process in which the medicament is mixed with a jelly or a chewable base at room temperature.

To confirm the stability of the chewable tablet of the present invention, an acceleration test was performed on the product prepared by the present process under certain condition ((1) room temperature, (2) 40° C., relative humidity (RH) 75%) for certain period (for 6 months, tested every 0, 2, 4, 6 months) and the changes of physico-chemical properties were observed. As a result, the chewable tablet of the present invention did not change in properties, state and content of the effective medicament and it was suitable for both of microorganism limit test and heavy metal test. The chewable tablet, therefore, has been proved to have excellent stability.

In addition, the chewable tablet of the present invention provides taste mask effect to a bitter tasty medicament, which is contained in the medicament, and better chewing property and taste than the conventional tablets by means of an outer tasty chewable base.

The present invention is further illustrated with reference to the following examples and experiment which are not intended to be in any way limiting to the scope of the invention as claimed.

EXAMPLE 1

Preparing Medicinal Chewing Gum Tablet

Dimenhydrinate, meclazine.HCl, acetaminophen, asprin or phenylpropanolamine.HCl was used for medicinal chewing gum tablet as a medicament.

1) medicinal chewing gum tablet with sugars

a) gum base
in one tablet

gum base	600 mg
lecithin	9 mg
hydrogenated palm oil	30 mg
liquid glucose	700 mg
sorbitol solution	70 mg
dextrose	340 mg
sugar	940 mg
aspartame	10 mg
glycerin	q.s.
flavoring agent	q.s.

b) jelly base
in one tablet

pectin	29 mg
sorbitol	120 mg
liquid glucose	220 mg
sugar	400 mg
citric acid	q.s.

2) sugar-free medicinal chewing gum tablet

a) gum base
in one tablet

gum base	300 mg
lecithin	12 mg
isomalt	415 mg
aspartame	q.s.
flavoring agent	q.s.

b) jelly base
in one tablet

pectin	35 mg
sorbitol	70 mg
liquid maltitol	160 mg
isomalt	430 mg
citric acid	q.s.
flavoring agent	q.s.

EXAMPLE 2

Preparing Chewing Hard Candy Tablet

Eleutherococcus senticosus extracts or cetylpyridinium chloride was used for chewing hard candy tablet as a medicament.

1) chewing hard candy tablet with sugars

a) candy base
in one tablet

sugar	2500 mg
liquid glucose	1750 mg
citric acid	q.s.
coloring agent	q.s.
flavoring agent	q.s.

b) jelly base
in one tablet

pectin	29 mg
sorbitol	120 mg
liquid glucose	220 mg
sugar	400 mg
citric acid	q.s.

2) sugar-free chewing hard candy tablet

a) candy base

-continued

in one tablet	
isomalt	2120 mg
aspartame	q.s.
citric acid	q.s.
coloring agent	q.s.
flavoring agent	q.s.
b) jelly base	
in one tablet	
pectin	35 mg
sorbitol	70 mg
isomalt	160 mg
citric acid	430 mg
flavoring agent	q.s.

EXAMPLE 3

Preparing Chewing Soft Candy Tablet

Vitamins; a mixture of vitamins and minerals; gastrointestinal agents such as aluminum hydroxide gel dried, domperidone, soluble azulene, L-glutamine and hydrotalcite; or natural plant extracts such as Sohgunjung-tang extracts and Sipchundaebo-tang extracts was used for chewing soft candy tablet as a medicament.

1) chewing soft candy tablet with sugars	
a) candy base	
in one tablet	
sugar	1800 mg
lactose	400 mg
liquid glucose	1800 mg
glyceryl monostearate	20 mg
hydrogenated palm oil	320 mg
gelatin	8 mg
citric acid	q.s.
b) jelly base	
in one tablet	
pectin	29 mg
sorbitol	120 mg
liquid glucose	220 mg
sugar	400 mg
citric acid	q.s.
2) sugar-free chewing soft candy tablet	
a) candy base	
in one tablet	
Isomalt	1800 mg
liquid maltitol	1900 mg
arabic gum	150 mg
lecithin	240 mg
citric acid	q.s.
coloring agent	q.s.
flavoring agent	q.s.
b) jelly base	
in one tablet	
pectin	35 mg
sorbitol	70 mg
liquid maltitol	160 mg
Isomalt	430 mg
citric acid	q.s.
flavoring agent	q.s.

EXPERIMENT

Stability test

The tablet of the present invention was examined on the stability by means of the following. The tests such as appearance, microorganism limit, heavy metal and content were carried out under the condition of 40° C. and 75% RH for 6 months, and the result was shown in table 1.

In addition, the above tests were carried out under the condition of room temperature (25° C.) for 6 months, and the result was shown in table 2.

TABLE 1

Results under the condition of 40° C. and 75% RH

	Time			
Test	At base (0 month)	After 2 months	After 4 months	After 6 months
Appearance	Suitable	Suitable	Suitable	Suitable
Microorganism limit	Suitable	Suitable	Suitable	Suitable
Heavy metal	Suitable	Suitable	Suitable	Suitable
Content (%)	112.74	112.70	112.65	112.54

TABLE 2

Results under the condition of room temperature (25° C.)

	Time			
Test	At base (0 month)	After 2 months	After 4 months	After 6 months
Appearance	Suitable	Suitable	Suitable	Suitable
Microorganism limit	Suitable	Suitable	Suitable	Suitable
Heavy metal	Suitable	Suitable	Suitable	Suitable
Content (%)	112.74	111.96	111.96	111.94

As shown in the above, the chewable tablet of the present invention did not change in appearance, and the content of the medicament, and it was suitable for both of microorganism limit test and heavy metal test. The chewable tablet, therefore, has been proved to be stable in the process of circulation.

EFFECT OF THE INVENTION

As described distinctly in the above, the present invention provides the chewable tablet which has an advantage in bioavailability resulting from increased absorption rate, because it is dissolved or chewed in the mouth and then moved into gastrointestinal tract in a state of whole solution or granule. And the medicament contained in the chewable tablet of the present invention as an effective ingredient is not changed in physico-chemical properties and keeps the effect of medicament due to the unique preparation process.

In addition, the chewable tablet containing even a bitter tasty medicament can be taken by dissolving or chewing because of good taste and flavor, and the tablet is easy to carry and can be taken whenever and wherever without water, as well.

What is claimed is:

1. A chewable tablet comprising a core containing a medicament in a state of jelly or chewable base; and an outer layer of chewable base wrapping the core, wherein the said chewable base contains an enhancing agent of chewing property selected from the group consisting of isomalt and liquid maltitol and a keeping agent of hardness and extension property being a gum including gelatin or arabic gum.

2. The chewable tablet of claim 1 wherein said jelly base of the core is selected from the group consisting of pectin, sorbitol, maltitol, isomalt, liquid glucose, sugar, citric acid and flavoring agent.

3. The chewable tablet of claim 1 wherein said chewable base of the core or the outer layer is selected from the group consisting of gum, soft gum, soft nougat, soft candy, hard candy and caramel.

4. The chewable tablet of claim 3 wherein the tablet additionally contains excipients selected from the group consisting of sugars; a protecting agent of adhesion to oral cavity and crystallization of sugars; a flavoring agent; a souring agent; a coloring agent; and combinations thereof, according to the chewable base.

5. The chewable tablet of claim 4 wherein said sugar is selected from the group consisting of white sugar, liquid glucose, sorbitol, dextrose, isomalt, liquid maltitol, aspartame and lactose.

6. The chewable tablet of claim 4 wherein said protecting agent of adhesion to oral cavity and crystallization of sugars is selected from the group consisting of glycerin, lecithin, hydrogenated palm oil and glyceryl monostearate.

7. The chewable tablet of claim 1 wherein said keeping agent of hardness and extension property comprises 0.1–2.0 weight % by total weight of the ingredients.

8. The chewable tablet of claim 1 wherein said enhancing agent of chewing property is prepared at temperatures of 135–140° C. and under vapor pressure of 5.5 bar.

9. The chewable tablet of claim 1 wherein said medicament, which is contained in the core, is vitamins selected from the group consisting of vitamin A, vitamin B, vitamin B_1, vitamin B_2, vitamin B_6, vitamin C, vitamin E and vitamin K; natural plant extracts selected from the group consisting of Sohgunjung-tang extracts, Sipchundacho-tang extracts and *Eleutherococcus senticosus* extracts; organic compounds selected from the group consisting of dimenhydrinate, meclazine.HCl, acetaminophen, aspirin, phenylpropanolamine.HCl and cetylpyridinium chloride; or gastrointestinal agents selected from the group consisting of aluminum hydroxide gel dried, domperidone, soluble azulene, L-glutamine and hydrotalcite.

10. The chewable tablet of claim 4 wherein said sugar comprises 50–90 weight % by total weight of the ingredients.

11. The chewable tablet of claim 4 wherein said protecting agent of adhesion to oral cavity and crystallization of sugars comprises 0.04–2.0 weight % by total weight of the ingredients.

* * * * *

ANEXO 3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064109 A2

(51) International Patent Classification[7]: A61K 9/00

(21) International Application Number: PCT/GB02/00620

(22) International Filing Date: 14 February 2002 (14.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0103638.3	14 February 2001 (14.02.2001)	GB
60/280,044	30 March 2001 (30.03.2001)	US
09/827,158	5 April 2001 (05.04.2001)	US
0111597.1	11 May 2001 (11.05.2001)	GB
0121715.7	7 September 2001 (07.09.2001)	GB
09/951,022	12 September 2001 (12.09.2001)	US

(71) Applicant *(for all designated States except US)*: GW PHARMA LIMITED [GB/GB]; Porton Down Science Park, Salisbury, Wiltshire SP4 0JR (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WHITTLE, BRIAN [GB/GB]; Wortley House, 16 Eastbourne Road, Hornsea, Yorkshire HU18 1QS (GB). GUY, GEOFFREY [GB/GB]; South House, Piddletrenthide, Dorchester, Dorset DT2 7QP (GB).

(74) Agents: BOULT WADE TENNANT et al.; Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATIONS



(57) Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.

WO 02/064109 A2

PHARMACEUTICAL FORMULATIONS

The invention relates to pharmaceutical formulations for use in the administration of medicaments, in particular lipophilic medicaments, via mucosal surfaces.

Medicaments taken by mouth and swallowed are absorbed first into the blood perfusing the gastrointestinal tract. The venous drainage from the GI tract is into the blood perfusing the liver. This means that medicaments absorbed from the lumen of gastrointestinal tract are immediately presented to the liver - the major detoxifying organ of the body. In addition to protecting the organism from ingested toxins, the liver also metabolises medicaments which are treated in the same way. Blood from the liver then returns to the left side of the heart via the hepatic portal vein and reaches the rest of the systemic circulation. This first pass through the liver may result in the removal of a substantial proportion of an ingested medicament. The first pass effect is more pronounced for some drugs than others; in the case of cannabinoids more than 90% of an ingested dose is removed during the first pass.

Certain areas of the alimentary canal have a venous drainage which does not involve a first pass through the liver. These areas (the mucous membrane of the buccal cavity, under the tongue and the nasopharynx,, and also the distal rectum) drain directly into the left side of the heart. The avoidance of the first pass effect is the rationale for the use of buccal, nasal and sublingual formations, and also suppositories. Each of these types of formulation has advantages and disadvantages,

as follows:

Suppositories are subject to hygiene and patient compliance restrictions.

Formulations intended for administration to the nasal mucosae may cause pain or reflex sneezing, and in extreme cases cause irritation and damage to the nasal mucosae.

Sublingual formulations may stimulate the flow of saliva and it is difficult for patients to avoid swallowing when substantial amounts of saliva are produced. Buccal formulations may be subject to the same limitations.

Both sublingual and buccal formulations depend on the efficient transfer of medicament from a hydrophilic vehicle to the mucous membrane of the sublingual or buccal mucosae. Transfer of medicament through the interstices between or through epithelial cells is governed principally by the lipid solubility of the medicament. Where a drug is water insoluble this is a further barrier to absorption from the sublingual area. There are therefore physical and biological limitations on the therapeutic usefulness of lipophilic medicaments, such as for example cannabis and cannabinoids, given by mouth and swallowed.

The present invention relates to formulations which are particularly suitable for use for administration of lipophilic medicaments via a mucosal surface such as, for example, the sublingual mucosa or the buccal mucosa.

Therefore, in accordance with a first aspect of the invention there is provided a pharmaceutical

formulation for use in administration of a lipophilic medicament via a mucosal surface comprising at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament.

By direct experiment it has been shown that lipophilic medicaments can be effectively brought into intimate contact with the absorptive mucous membrane when they are formulated into a self-emulsifying formulation.

In the context of the present invention the following terms will be understood to have the following meanings:

A "self-emulsifying agent" is an agent which will form an emulsion when presented with an alternate phase with a minimum energy requirement. In contrast, an emulsifying agent, as opposed to a self-emulsifying agent, is one requiring additional energy to form an emulsion. In the case of the spray formulations disclosed herein, self-emulsification occurs on contact with the alternative phase (saliva).

A "primary" (self) emulsifier is one whose primary function is as a (self) emulsifier.

A secondary (self) emulsifier is one whose secondary function is as a (self) emulsifier. The secondary (self) emulsifier may have another function, e.g. as a solubiliser or viscosifying agent.

Generally a self-emulsifying agent will be a

soluble soap, a salt or a sulphated alcohol, especially a non-ionic surfactant or a quaternary compound. These are often known as self-emulsifying grades (SE grade), e.g. SE grade glyceryl mono oleate, and SE grade glyceryl monostearate.

The "Hydrophilic Lipophilic Balance" (HLB) system, the balance between the hydrophilic and lipophilic moieties of a surface-active molecule, is used as a basis for rational means of selecting and classifying emulsifying agents. In the HLB system each emulsifying agent is assigned a number between 1 and 20 (see Pharmaceutical Codex). Emulsifying agents with HLB values of between 3 and 6 are lipophilic and form water-in-oil emulsions, while values of 8 to 18 indicate predominantly hydrophilic characteristics and the formation of oil-in-water emulsions. The preferred emulsifying agents for use in the present invention generally exhibit HLB values of between 8 and 18.

Surprisingly, formulations according to the invention do not produce reflex salivation as salivary secretion is attracted into the dose unit, and forms *in situ* an emulsified mass. Further, the mass so formed adheres to and forms a layer on the mucosal surface, typically the buccal and/or sublingual mucosae, and thereby provides a controlled release formulation.

In a preferred embodiment the formulation according to the invention is not a propellant-driven aerosol or liquid spray.

The preparation of liquid formulations for oropharangeal delivery of cannabinoids poses a number of problems. First, it is necessary to deliver at

least 1.0mg, more preferably at least 2.5mg and even more preferably at least 5mg of cannabinoids per 0.1ml of liquid formulation to achieve a therapeutic effect in a unit dose. In this regard a patient may require up to 120mg cannabinoid/day, on average around 40mg/day to be taken in a maximum of six doses.

In the case of a sublingual or buccal delivery, this means delivering this quantity of the active ingredient in an amount of formulation which will not be swallowed by the patient, if the active ingredient is to be absorbed transmucosally.

Whilst such amounts can be achieved by dissolving the cannabinoid in ethanol as the solvent, high concentrations of ethanol provoke a stinging sensation and are beyond the limit of tolerability.

There is thus a need to use a co-solvent in order to reduce the amount of ethanol, whilst still enabling sufficient quantities of cannabinoid to be solubilised.

The applicant has discovered that the choice of co-solvent is limited and should be selected from either:

i) a co-solvent which acts as a solubility enhancer, or

ii) a co-solvent which has a solubilizing effect sufficient to allow enough cannabinoid to be solubilised in a unit dose, namely at least 1.0mg/0.1ml of formulation, and which allows the amount of solvent present to be reduced to a level which is within the limits of patient tolerability.

Particularly suitable co-solvents with reference

to i) above are polyoxyethylene castor oil derivatives, particularly cremophor.

Particularly suitable co-solvents with reference to ii) above are propylene glycol and glycerol.

Most preferably the formulation according to the invention is a solid dosage form such as, for example, a solid gel (e.g. a gel which is flexible but which has dimensional stability), pastille, compressed tablet, lozenge, capsule etc, or a gel-spray.

The dosage units are preferably homogeneous in composition, but also included within the scope of the invention are multi-layered dosage units formed from layers of differing composition, for example two-layered tablets and gels, as illustrated in the accompanying Examples, in which the different layers contain different active ingredients and/or exhibit different release characteristics.

Gel-spray formulations may also include one or more solvents and optionally also one or more co-solvents.

Suitable solvents for use in gel-spray formulations include ethanol. Suitable co-solvents agents include glycerol.

Gel-sprays can be distinguished from "liquid" formulations on the basis of viscosity. Gel-sprays are generally more viscous than simple ethanolic solutions. Typically, the viscosity of a gel-spray will be in the range of 10,000-20,000 centipoises.

Suitable self-emulsifying agents which may be included into the formulations of the invention

include, *inter alia*, those substances which are indicated as primary and secondary emulsifiers in Table 2. Preferred self-emulsifying agents include glyceryl mono-oleate and glyceryl monostearate (particularly the self-emulsifying grade). With glyceryl mono-oleate and glyceryl monostearate (other than self-emulsifying grades) it is usual to add, for example, a small amount of alkali in order to produce a "self-emulsifying" agent.

For solid dosage formulations the total amount of self-emulsifying agent(s) included in the formulation is preferably at least 5% w/w, more preferably at least 10% w/w of the formulation.

For gel-spray formulations the total amount of self-emulsifying agent(s) included in the formulation is preferably at least 2% w/w, more preferably at least 5% w/w of the formulation.

The total amount of self-emulsifier generally varies in proportion to the total amount of active ingredient (lipophilic medicament) included in the formulation; the greater the amount of active ingredient, the greater the amount of self-emulsifying agents. The formulations according to the invention are intended to accommodate amounts greater than 1% of the active ingredient. Most preferably the relative proportions of self-emulsifying agent to active ingredient should be between 1% self-emulsifier per 10% active and 1% self-emulsifier per 5% active. The total amount of self-emulsifying agents may also be varied in order to produce a formulation with the desired dissolution/disintegration characteristics in the mouth, since it is observed by experiment that increasing the amount of self-emulsifying agent has the effect of increasing dissolution/disintegration

time (see Example 14).

The formulation may further comprise one or more viscolising agents (agents which increase viscosity). Suitable viscolising agents include those listed in Table 2 below.

Preferably the viscolising agent(s) is/are not block copolymers of oxyethylene and oxypropylene. More preferably the viscolising agents are non nonionic surfactants. In the latter case these formulations may contain self-emulsifying agents which are nonionic surfactants, but additionally contain at least one viscolising agent which is not a nonionic surfactant.

In a preferred embodiment, the formulation may comprise at least one viscolising agent which is solubilised by the action of an enzyme present in saliva. Examples of such a viscolising agents include starches, for example pre-gelatinised starch, which are solubilised by the action of salivary amylase.

The inclusion of viscolising agents which are susceptible to enzymatic degradation may result in the formation of an *in situ* mass comprising the lipophilic medicament which has the characteristics for optimising absorption from the buccal cavity and sublingual mucosae. This has the advantage of allowing solid gels to be rapidly dissolved (in, for example, a matter of minutes).

A wide variety of hydrophilic viscolising agents have been used in pharmaceutical preparations and it is known that gels formed by hydration of these substances may have a surface electrical charge. Table 2 lists some agents (but without restriction to

the scope of the invention), which have this property, and indicates those that have received regulatory approval in preparations intended for oral administration. The table also indicates the sign of the surface charge, where it is known.

In a preferred embodiment the formulation may comprise at least one viscolising agent that when hydrated forms a gel having a positive surface charge and at least one viscolising agent that when hydrated forms a gel having a negative surface charge. In the most preferred embodiment the formulation may comprise at least one viscolising agent that when hydrated forms a gel having a positive surface charge which is a gelatin or glycogelatin and at least one viscolising agent that when hydrated forms a gel having a negative surface charge which is a starch, pre-gelatinised starch, acacia or polydextrose.

Surprisingly it has been found that by selective admixture of materials producing gels of opposing electrical charge it is possible to modify the solubility characteristics of the resulting mixture and to control the rate of release of medicament from this formulation, in particular by solubilisation of at least one component by the amylolytic enzyme present in saliva.

It is possible to modify the physical properties of the dosage form by varying the total amount of viscolising agents and also by varying the proportion of the materials forming gels of positive and negative surface charge. In general, increasing the relative amount of positively charged viscolising agent (e.g. gelatin or glycogelatin) has the effect of slowing down dissolution/dispersion in the mouth, whereas increasing the relative amount of negatively charged

viscolising agent (e.g. starch or pre-gelatinised starch) has the effect of speeding up dissolution/dispersion in the mouth (see Example 14). The proportion of positive and negatively charged viscolising agents included in the formulation may therefore be varied to produce a dosage form which exhibits the desired release characteristics.

For solid dosage forms the total amount of viscolising agent(s) (including any gelling agents) included in the formulation will preferably be greater than 60% w/w of the formulation.

For gel-spray dosage forms the total amount of viscolising agent(s) included in the formulation will preferably be greater than 1% w/w of the formulation, most preferably greater than 2% w/w of the formulation. Preferred viscolising agents for inclusion into gel-spray formulations include, for example, carboxymethyl cellulose.

Further excipients may be included in the formulations according to the invention as appropriate. For example, the formulations may include one or more antioxidants. Preferred antioxidants include α-tocopherol, ascorbyl palmitate, butylated hydroxy anisole (BHA) etc. The formulation may also include one or more colouring agents. Suitable colouring agents include, for example, curcumin or chlorophylls.

The accompanying examples illustrate formulations which optimise the absorption of strongly lipophilic medicaments through the mucosae of the buccal and sublingual epithelia and result in the required pharmacokinetic profile for optimum therapeutic action. The formulations contain at least one

self-emulsifying component that in contact with saliva forms a viscous emulsion which adheres, reversibly, to the mucous membrane, without causing irritation or damage, or stimulating excessive salivation. When the dosage form is introduced into the mandibular or maxillary fossae, or placed under the tongue it hydrates and adheres to the mucosae. The hydrated, emulsified mass so formed remains in contact with a large area of the buccal and sublingual mucosae, and releases medicament over a period of time.

The controlled release characteristics of the formulation, i.e. disintegration time, may be varied by varying the relative amounts of excipients included into the formulation, in particular the amounts of self-emulsifying agents and viscolising agents, if present. The disintegration characteristics may therefore be varied to suit the type of lipophilic medicament included in the formulation, since it is desirable that the formulation remain in contact with the mucosal surface for a period of time sufficient to allow substantially all of the lipophilic medicament to be absorbed through the mucosal surface into the systemic circulation. The rate at which the lipophilic medicament is absorbed is obviously dependent on the nature of the medicament. In the case of cannabinoids, significant absorption through the buccal or sublingual mucosa is achieved in a period of about 10 minutes. It is therefore desirable that any formulation for delivery of cannabinoids remain substantially intact and in contact with the mucosal surface for at least this time.

Most preferably formulations according to the invention will disintegrate completely within a period of from 0.1-60 minutes, more preferably within 0.5-15 minutes, but formulations within the scope of the

invention have been produced in which disintegration time is at least 90 minutes.

Table 1 lists examples of medicaments which can be included in the formulations according to the invention. Classes of compound are indicated in **bold**. Examples of compounds are intended to be illustrative rather than limiting to the invention. The person skilled in the art will appreciate that compounds having a unit dose less than 10mg are most conveniently given in the form of small tablets as described in Example 6. Compounds where the unit dose is greater are most conveniently included in the gel formulations which can accommodate higher unit doses of medicament.

Table 1

CLASS OF MEDICAMENT	EXAMPLE OF MEDICAMENT
Alkaloid-rich extracts of *Belladonna atropa*	Hyoscine Hyoscymine Atropine
Alkaloid-rich extracts of *Gallenthus spp.*	
Alkaloid-rich extracts of *Narcissus spp.*	
Alkaloid-rich extracts of opium	Morphine Codeine Diamorphine
Alkaloid-rich extracts of Pilocarpine	Pilocarpine salycilate
Anti-asthmatics	Terbutaline
Antibacterials	
Antifungals	Fluconazole
Anti-inflammatory agents	Benzidamine Pyroxicam
Antivirals	Acyclovir Zidovudine
Beclomethasone	
Cannabinoid-rich fractions of *Cannabis sativa* and *Cannabis indica*, and chemovars derived from them	
Cannabinoids	Δ^9 Tetrahydrocannabinol (THC) Cannabidiol (CBD) Cannabinol (CBN)

Cannabinoid-rich fractions containing cannabinoids other than THC, CBD or CBN as the most abundant component	
Cardiovascular Agents	Nifedipine Diltiazem Verapamil
Centrally acting analgesics	Butorphenol Buprenorphine Fentanyl
Antiangina agents	Nitrates
Fluticasone proprionate	
Polyunsaturated fatty acid triglycerides	n-3 and n-6 PUFAs Acylglycerols
Sympathomimetic amines	Salbutamol

Table 2 lists pharmaceutically acceptable excipients and types of excipient which can be included (without limitation of the invention) to give a suitable degree of viscosity when the dose unit is placed in contact with saliva. The dosage form may be formed by fusion or compression into a mould sealable to exclude light and air.

Table 2 lists classes of compound and examples of agents which can be used to produce emulsification, mucoadhesion and an increase in viscosity. The designation as primary (1°) or secondary (2°) emulsifier is for convenience. Many of the agents can be used alone or in combination to fulfil the role of primary or secondary emulsifier.

Table 2

Compound Class/Example	Preferred Quantity % w/w	Surface Charge (where known)	Regulatory Approval	Comments
Acacia		Negative	M	Forms a viscous coacervate with positively charged gels such as gelatin
Alcohols				
Cetostearyl	1 – 20		F,M	2° emulsifier
Cetyl	1 – 15			2° emulsifier
Anionic emulsifying wax	3 – 30		M	1° self emulsifier
Cellulose, hydroxypropyl	5 - 35		G,F,M,R	2° emulsifier, stabiliser, viscoliser
Diethanolamine (DEA)	1 - 10		M,F,R	1° self emulsifier
Gelatin	40 - 70	Positive	F,M	Gelling agent
Glyceryl monooleate	1 - 30		G,F,R	1° self emulsifier, solubiliser
Glyceryl monostearate	2 - 20		G,M,F,R	1° self emulsifier, solubiliser, tablet lubricant
Lecithin	2 - 15		G,M,F,R	2° emulsifier
Medium Chain Triglycerides	1 - 10		G, R	2° emulsifier, solvent
Methylcellulose	1 - 5		G,M,F,R	2° emulsifier, viscoliser
Nonionic emulsifying wax	5 - 25		M,R	1° emulsifier, viscoliser
Poloxamer	2 - 10		M,F,R	2° emulsifier, viscoliser
Polydextrose		Negative		Viscoliser
Polyethoxylated Castor Oil	1 - 10		M,F,R	1° self emulsifier, solubiliser, stabiliser
Polyoxyethylene alkyl ethers	10 - 20		M,R	1° self emulsifier, solubiliser
Polyoxyethylene ethers (Macrogols)	1 - 15		M,R	1° self emulsifier, solubiliser, wetting agent
Polyoxyethylene fatty acid esters (polysorbates)	0.5 - 10		G,M,F,R	1° self emulsifier, solubiliser
Polyoxyethelene stearates	0.5 - 10		M,F,R	2° emulsifier, solubiliser
Pregelatinised starch	1 - 20	Negative	G,F,R	Coacervates with gelatin, viscolisers
Propylene glycol alginate	1 - 5		G,M,F,R	2° emulsifier, viscoliser
Sodium lauryl sulfate	0.5 - 2.5		G,M,F,R	1° self emulsifier
Sorbitan esters (sorbitan fatty acid esters)	0.1 - 15		Food, M,F,R	1° self emulsifier, solubiliser
Starch	2 - 15	Negative	G,M,F,R	Viscoliser, tablet diluent, disintegrant
Tri-sodium citrate	0.3 - 4		G,M,F,R	2° emulsifier, pH modifier, sequestering agent

M – Monograph in major pharmacopoeias
F – Accepted in FDA Inactive Ingredients Guide
R – Included in parenteral medicines, licensed in the UK or Europe
G – Generally Regarded as Safe

In accordance with a second aspect of the invention there is provided a pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, the formulation comprising at least one lipophilic medicament, at least one solvent, at least one co-solvent, which is preferably also a solubilising agent, and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, characterised in that the total amount of solvent and co-solvent present in the formulation is greater than 55% w/w of the formulation.

In a preferred embodiment this formulation may be a liquid dosage form, for example an aerosol, liquid spray or drops. The technical principle of delivery of a lipophilic active ingredient to a mucosal surface in a self-emulsifying formulation which adheres to the mucosa for sufficient time to allow absorption of the lipophilic medicament can thus be extended to liquid dosage forms. A preferred embodiment is a liquid formulation administered via a pump-action spray.

A pump-action spray is found to be particularly beneficial when it comes to delivering cannabinoids. Indeed previously people have considered pump-action sprays to be unsuitable for drug delivery and people have focussed their attention on solvent systems including a propellant.

Whilst it has been recognised that there are disadvantages with such systems, including the speed of delivery, those skilled in the art have tried to address this by slowing the propellant by altering the nozzle. The applicants have found that by using a pump spray with their formulations they are able to produce a spray in which the particles have a mean aerodynamic particle size of between 15 and 45 microns, more particularly between 20 and 40 microns and an average of about 33 microns. These contrast with particles having a mean aerodynamic particle size of between 5 and 10 microns when delivered using a pressurised system.

In fact, comparative tests by the applicant have shown such a pump-action spray system to have advantages in being able to deliver the active components to a larger surface area within the target area. This is illustrated with reference to the accompanying Example 12.

The variation in particle distribution and sprayed area has been demonstrated by direct experiment. A formulation as described in the accompanying Example 12 was filled into a pump action spray assembly (Valois vial type VP7100 actuated). The same formulation was filled into a pressurised container powered by HFA 134a.

Both containers were discharged at a distance of 50ml from a sheet of thin paper held at right angles to the direction of travel of the jet. The pattern of spray produced in both cases by discharge of 100µl was then visualised against the light. In both cases the pattern of discharge was circular and measurements were as follows:

	Mean Diameter (mm)	Mean Area (mm^2)
Pump Action Spray	23	425.5
Pressurised Spray	16	201.1

The pressurised spray produced pooling of liquid at the centre of the area. The pump action spray gave a more even pattern of pooling and less "bounce back". There was also a significantly greater area covered by the pump action spray. The conditions under which this test was carried out are relevant to the in-practice use of the device. A wider area of buccal mucosa can be reached by the PAS compared with the pressurised spray.

In a preferred embodiment the total amount of solvent and co-solvent present in the formulation, absent of propellant, is greater than 65% w/w, more preferably greater than 70% w/w, more preferably greater than 75% w/w, more preferably greater than 80% w/w, more preferably greater than 85% w/w of the formulation. Most preferably the total amount of solvent and co-solvent present in the formulation is in the range from 80% w/w to 95% w/w of the formulation.

Preferred solvents for use in this formulation are lower alkyl (C_1-C_4) alcohols, most preferably ethanol.

Preferred co-solvents for use in this formulation include propylene glycol, glycerol, macrogols and also co-solvents which are also solubilising agents, of which preferred examples are polyoxy hydrogenated castor oils. It is within the scope of the invention for the "solubilising agent" and "self-emulsifying agent" included in the formulation to be the same

chemical substance.

In the content of this application the term "solubilising agent" refers to a substance which preferably increases solubility of the active ingredient (i.e. the lipophilic medicament) within the formulation. In the formulation according to this second aspect of the invention a solubilising agent may be included to overcome the problem of improving solubility of the active ingredient (lipophilic medicament) in formulations containing a limited amount of ethanol. Thus the addition of a solubilising agent generally has the effect of increasing the amount of active ingredient which can be incorporated into the formulation, whilst maintaining patient tolerability.

The advantage of including a co-solvent is particularly well illustrated with reference to formulations wherein the lipophilic medicament comprises one or more cannabinoids. Cannabinoid generally have limited solubility in many solvents and this places a limitation on the amount of cannabinoids which may be incorporated into pharmaceutical formulations. For example aerosol sprays containing ethanol plus a propellant could only stabilise 0.7mg of THC per 0.1ml of liquid formulation. As a consequence, multiple applications of these formulations must be administered to the patient in order to achieve a pharmaceutically significant dose of the active cannabinoid. The addition of a co-solvent which is a better Solubiliser than standard propellants, for example propylene glycol, glycerol, a macrogol or a polyoxy hydrogenated castor oil, as taught by the present invention, enables incorporation of a far greater about of active cannabinoids which in turn means that it is possible

to administer a pharmaceutically relevant dose of cannabinoid in a single application of the formulation.

In a preferred embodiment the formulation contains ethanol as a solvent and propylene glycol as co-solvent. In this embodiment the ratio of ethanol to propylene glycol present in the formulation is preferably in the range from 4:1 to 1:4 and is most preferably 1:1.

In a further preferred embodiment the formulation contains ethanol as a solvent and a polyoxy hydrogenated castor oil (most preferably cremophor RH40) as a co-solvent/solubilising agent. In this embodiment the amount of polyoxy hydrogenated castor oil present in the formulation is preferably between 5% and 55% w/w, more preferably between 20% and 40% w/w and most preferably 30% w/w of the total amount of polyoxy hydrogenated castor oil plus ethanol (% w/w) present in the formulation, and is more preferably of the total amount of polyoxy hydrogenated castor oil plus ethanol (% w/w) present in the formulation. The total amount of polyoxy hydrogenated castor oil plus ethanol may be up to 97% w/w of the formulation.

Suitable self-emulsifying agents which may be included in this formulation are those listed in Table 2, and described above in connection with the first aspect of the invention. Most preferred are glyceryl mono-oleate and glyceryl monostearate (preferably the self-emulsifying grade).

In this formulation the total amount of self-emulsifying agents is preferably greater than 1% w/w of the formulation.

Other excipients may be included in the formulation, such as antioxidants, flavourings etc, as described above. Most preferably the formulation does not contain any propellant, such as is commonly present in a propellant-driven aerosol formulation.

In a preferred embodiment liquid and gel-spray formulations according to the invention may be adapted for application to the buccal mucosae.

As a result of direct investigation, it has been found that in some circumstances there may be limitations on the applicability of medicaments to the mucosal surface under the tongue, which limit the usefulness of sublingual applications. Certain highly lipid-soluble medicaments (including cannabinoids and extracts of cannabis) can only be brought into solution by dissolving in (principally) non-aqueous solvents. These solvents, such as propylene glycol, ethanol (with or without the addition of glycols) and solubilising agents, are pharmaceutically acceptable but when dropped or sprayed onto the sublingual mucosae (and dependent on concentration of ethanol) may produce a hot stinging sensation. The stinging sensation so produced may cause reflex swallowing. The result is that a proportion of the dose may then be swallowed by stimulation of the swallowing reflex. A variable proportion of the dose is absorbed from the GIT below the level of the oropharynx and is subject to the variability of absorption due to the first pass effect. These factors lead to variable absorption of medicaments by what is assumed to be the sublingual route.

It has been found that application of solutions or emulsifiable formulations direct to the buccal surface, either as drops or preferably as a pump

action spray, solves the first pass problem and has a number of other unexpected advantages, as follows:

(1) When a conventional pressurised aerosol is directed into the oropharyngeal space, a cloud of particles can be seen escaping from the mouth indicating loss of medicament. This can be avoided by spraying directly onto the buccal surface, away from the area under the tongue. The problem can be more completely addressed by using a pump action, manually-operated spray (PAS). The PAS operates at lower pressure, produces a spray with a larger mean aerodynamic diameter (e.g. between 15 and 45 microns) and can be directed to the buccal rather than sublingual areas of the mouth;

(2) Avoidance or minimisation of the unacceptable stinging sensation (the buccal mucosa is less sensitive than the sublingual area in this respect);

(3) Substantial immobilisation of the dose of medicament in contact with the buccal surface, allowing for absorption from a site not disturbed by normal salivation. After application, the buccal mucosa returns to its normal position in apposition to the outer gingival surface of the maxilla or mandible and is there held in a pocket in contact with absorbing surfaces;

(4) Minimisation of loss of dose by swallowing. The swallowing reflex is not stimulated by buccal application, and because the medicament is in a closed space it is possible for the patient to swallow saliva produced normally without disturbing the buccal pocket;

(5) The area under the absorption curve (AUC) is

similar for sublingual and buccal formulations, for cannabinoids. After buccal administration there is a substantial reduction in the amount of the primary (11-hydroxy-) metabolite of the cannabinoids. This confirms that a greater proportion of cannabinoid/active is absorbed transmucosally than from the sublingual area. A higher degree of absorption is taking place from the buccal mucosae than from the sublingual mucosae following the use of the buccal formulations described below (see Example 12).

Nature of the lipophilic medicament

The examples illustrate the way in which sublingual and buccal formulations can be made from intractable, lipophilic drug substances such as cannabinoids or glyceride trinitrate (GTN). However, the utility of the invention is not limited to this class of active ingredient and Table 1 lists some of the active ingredients by reference to class, and individual drugs which can be formulated according to the present invention.

Where medicaments are soluble in water it is possible to disperse the medicament over the epithelium of the buccal cavity and the sublingual mucosae. Provided that the medicament molecule (if ionised) has the appropriate ionisation constant, it will pass through the epithelium and be absorbed into the systemic circulation. Uncharged, lipid molecules will only pass into, and through, the oropharyngeal mucosae if they are brought into intimate contact with the mucosae.

Where medicaments are water insoluble, dispersion of oily materials in the aqueous environment of the

mouth is uneven. When oily medicaments are brought into intimate contact with the mucosae there is an opportunity for absorption through the epithelium. However, oily substances have an unpleasant mouth feel generally, and it is necessary to formulate them in order to overcome this problem. Emulsions have a mouthfeel which is more acceptable than oil to most patients. Compliance (i.e. temporary abstinence from swallowing) is therefore improved.

Cannabinoids, the active constituents of cannabis, are soluble in highly non-polar solvents (i.e. in substances such as chloroform, dichloromethane and high concentrations of alcohol); they also have limited solubility in glycols. Some of these solvents are pharmaceutically unacceptable, and the pharmaceutically acceptable solvents need to be used in high concentrations to produce solutions which can be applied to the oral mucosae. Solubility in some of these solvents imposes a ceiling on the dose which can be given using conventional pharmaceutical methods of formulation.

In order to be absorbed from the sublingual/buccal mucosae it is essential that the cannabinoid is brought into intimate contact with the surface of mucosal cells. To this extent the formulation must be "wettable". Tetrahydrocannabinol (THC) is an oily liquid at room temperature; cannabidiol is an oil soluble solid. Both have very low solubility in aqueous excipients.

By direct experiment it has been discovered that formulation of a cannabinoid with at least one self-emulsifying surfactant, surprisingly results in the generation of an oil in water (o/w) emulsion in a few seconds, i.e. as soon as the product is wetted by

saliva. Viscolising agents, optionally with adhesive properties, may be added to the formulation to ensure that the emulsion so formed adheres to the epithelium of the buccal cavity. Carbohydrate-based viscolisers are degraded by amylolytic enzymes in saliva and a combination of viscolisers can be devised such that there is progressive reduction in viscosity with dwell time in the buccal cavity. Advantage can also be taken of the effect of certain glycols and sugar alcohols which enhance formulations containing cannabinoids by, for example, allowing ethanol levels to be reduced. Sugars, which are rapidly soluble, speed dissolution. Where it is necessary to use non-cariogenic solubilisers, sugar alcohols are used preferentially.

Therefore, in accordance with a third aspect of the invention there is provided pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, which formulation comprises at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, wherein the lipophilic medicament is at least one extract from a cannabis plant.

A "plant extract" is an extract from a plant material as defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research.

"Plant material" is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers,

fruits, seeds, berries or parts thereof) as well as exudates.

The term "Cannabis plant(s)" encompasses wild type *Cannabis sativa* and also variants thereof, including cannabis chemovars which naturally contain different amounts of the individual cannabinoids, *Cannabis sativa* subspecies *indica* including the variants var. *indica* and var.*kafiristanica*, *Cannabis indica* and also plants which are the result of genetic crosses, self-crosses or hybrids thereof. The term "Cannabis plant material" is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants. For the avoidance of doubt it is hereby stated that "cannabis plant material" includes dried cannabis biomass.

In the context of this application the terms "cannabis extract" or "extract from a cannabis plant", which are used interchangeably encompass "Botanical Drug Substances" derived from cannabis plant material. A Botanical Drug Substance is defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: "A drug substance derived from one or more plants, algae, or macroscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction, or other similar processes." A botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources. Thus, in the case of cannabis, "botanical drug substances" derived from cannabis plants do not include highly purified, Pharmacopoeial grade

cannabinoids.

"Botanical drug substances" derived from cannabis plants include primary extracts prepared by such processes as, for example, maceration, percolation, extraction with solvents such as C1 to C5 alcohols (e.g. ethanol), Norflurane (HFA134a), HFA227 and liquid carbon dioxide under pressure. The primary extract may be further purified for example by supercritical or subcritical extraction, vaporisation and chromatography. When solvents such as those listed above are used, the resultant extract contains non-specific lipid-soluble material. This can be removed by a variety of processes including "winterisation", which involves chilling to -20°C followed by filtration to remove waxy ballast, extraction with liquid carbon dioxide and by distillation.

Preferred "cannabis extracts" include those which are obtainable by using any of the methods or processes specifically disclosed herein for preparing extracts from cannabis plant material. The extracts are preferably substantially free of waxes and other non-specific lipid soluble material but preferably contain substantially all of the cannabinoids naturally present in the plant, most preferably in substantially the same ratios in which they occur in the intact cannabis plant.

Botanical drug substances are formulated into "Botanical Drug Products" which are defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: "A botanical product that is intended for use as a drug; a drug

product that is prepared from a botanical drug substance."

In accordance with a fourth aspect of the invention there is provided a pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, which formulation comprises at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, wherein the lipophilic medicament comprises a combination of two or more natural or synthetic cannabinoid.

In this embodiment the "cannabinoids" may be highly purified, Pharmacopoeial Grade substances and may be obtained by purification from a natural source or via synthetic means. The cannabinoids will include, but are not limited to, tetrahydrocannabinoids, their precursors, alkyl (particularly propyl) analogues, cannabidiols, their precursors, alkyl (particularly propyl) analogues, and cannabinol.

In a preferred embodiment the lipophilic medicament comprises any combination of two or more cannabinoid selected from tetrahydrocannabinol, Δ^9-tetrahydrocannabinol, Δ^9-tetrahydrocannabinol propyl analogue, cannabidiol, cannabidiol propyl analogue, cannabinol, cannabichromene, cannabichromene propyl analogue and cannabigerol.

The principles of formulation suitable for administration of cannabis extracts and cannabinoids can also be applied to other medicaments such as

alkaloids, bases and acids. The requirements are that, if the medicament is insoluble in saliva, it should be solubilised and/or brought into the appropriate unionised form by addition of buffering salts and pH adjustment.

The formulations according to the invention may be used for delivery of extracts of the cannabis plant and also individual cannabinoids, or synthetic analogues thereof, whether or not derived from cannabis plants and combinations of cannabinoids. "Cannabis plants" includes wild type *Cannabis sativa* and variants thereof, including cannabis chemovars which naturally contain different amounts of the individual cannabinoids. In particular, the invention provides formulations of cannabis based medicine extracts (CBME).

Cannabis has been used medicinally for many years, and in Victorian times was a widely used component of prescription medicines. It was used as a hypnotic sedative for the treatment of "hysteria, delirium, epilepsy, nervous insomnia, migraine, pain and dysmenorrhoea". The use of cannabis continued until the middle of the twentieth century, and its usefulness as a prescription medicine is now being re-evaluated. The discovery of specific cannabinoid receptors and new methods of administration have made it possible to extend the use of cannabis-based medicines to historic and novel indications.

The recreational use of cannabis prompted legislation which resulted in the prohibition of its use. Historically, cannabis was regarded by many physicians as unique; having the ability to counteract pain resistant to opioid analgesics, in conditions such as spinal cord injury, and other forms of

neuropathic pain including pain and spasm in multiple sclerosis.

In the United States and Caribbean, cannabis grown for recreational use has been selected so that it contains a high content of tetrahydrocannabinol (THC), at the expense of other cannabinoids. In the Merck Index (1996) other cannabinoids known to occur in cannabis such as cannabidiol and cannabinol were regarded as inactive substances. Although cannabidiol was formerly regarded as an inactive constituent there is emerging evidence that it has pharmacological activity, which is different from that of THC in several respects. The therapeutic effects of cannabis cannot be satisfactorily explained just in terms of one or the other "active" constituents.

It has been shown that tetrahydrocannabinol (THC) alone produces a lower degree of pain relief than the same quantity of THC given as an extract of cannabis. The pharmacological basis underlying this phenomenon has been investigated. In some cases, THC and cannabidiol (CBD) have pharmacological properties of opposite effect in the same preclinical tests, and the same effect in others. For example, in some clinical studies and from anecdotal reports there is a perception that CBD modifies the psychoactive effects of THC. This spectrum of activity of the two cannabinoids may help to explain some of the therapeutic benefits of cannabis grown in different regions of the world. It also points to useful effects arising from combinations of THC and CBD. These have been investigated by the applicant. Table 3 below shows the difference in pharmacological properties of the two cannabinoids.

Table 3

Effect	THC	THCV	CBD	CBDV	Reference
CB_1 (Brain receptors)	++		±		Pertwee *et al*, 19
CB_2 (Peripheral receptors)	+		-		
CNS Effects					
Anticonvulsant †	--		++		Carlini *et al*, 19
Antimetrazol	-		-		GW Data
Anti-electroshock	-		++		GW data
Muscle Relaxant	--		++		Petro, 1980
Antinociceptive	++		+		GW data
Catalepsy	++		++		GW data
Psychoactive	++		-		GW data
Antipsychotic	-		++		Zuardi *et al*, 199
Neuroprotective antioxidant	+		++		Hampson A J *et al*
activity*	++		-		1998
Antiemetic	+		+		
Sedation (reduced					
spontaneous activity)	++				Zuardi *et al*, 199
Appetite stimulation			++		
Appetite suppression	-		++		
Anxiolytic					GW data
Cardiovascular Effects					
Bradycardia	-		+		Smiley *et al*, 197
Tachycardia	+		-		
Hypertension $	+		-		
Hypotension $	-		+		Adams *et al*, 1977
Anti-inflammatory	±		±		Brown, 1998
Immunomodulatory/anti-inflammatory activity					
Raw Paw Oedema Test	-		++		GW data
Cox 1					GW data
Cox 2					GW data
TNFá Antagonism	+	+	++	++	
Glaucoma	++		+		

* Effect is CB1 receptor independent.

† THC is pro convulsant

$ THC has a biphasic effect on blood pressure; in naïve patients it may produce postural hypotension and it has also been reported to produce hypertension on prolonged usage. GW

Internal Report No 002/000159.

From these pharmacological characteristics and from direct experiments carried out by the applicant it has been shown, surprisingly, that combinations of THC and CBD in varying proportions are particularly useful in the treatment of certain therapeutic conditions. It has further been found clinically that the toxicity of a mixture of THC and CBD is less than that of THC alone.

Accordingly, in a fifth aspect the present invention provides pharmaceutical formulations comprising cannabinoids which have specific ratios of CBD to THC, which have been found to be clinically useful in the treatment or management of specific diseases or medical conditions.

In a further aspect the invention also provides pharmaceutical formulations which have specific ratios of tetrahydrocannabinovarin (THCV) or cannabidivarin (CBDV). THCV and CBDV (propyl analogues of THC and CBD, respectively) are known cannabinoids which are predominantly expressed in particular Cannabis plant varieties and it has been found that THCV has qualitative advantageous properties compared with THC and CBD respectively. Subjects taking THCV report that the mood enhancement produced by THCV is less disturbing than that produced by THC. It also produces a less severe hangover.

In a still further aspect the invention provides pharmaceutical formulations which have specific ratios of THCV to THC. Such formulations have been found to be particularly useful in the field of pain relief and appetite stimulation.

In a preferred embodiment the formulations provided in accordance with the fifth and subsequent aspects of the invention, e.g. formulations containing specific ratios of cannabinoids may also have all the essential features of the "self-emulsifying" formulations described above.

The invention also provides methods of making the aforementioned pharmaceutical formulations as well as methods of using them to treat or manage specific diseases or conditions. Embodiments of formulations, methods and uses of the present invention are set out in the accompanying claims.

It has particularly been observed by the present applicants that the combinations of the specific cannabinoids are more beneficial than any one of the individual cannabinoids alone. Preferred embodiments are those formulations in which the amount of CBD is in a greater amount by weight than the amount of THC. Such formulations are designated as "reverse-ratio" formulations and are novel and unusual since, in the various varieties of medicinal and recreational Cannabis plant available world-wide, CBD is the minor cannabinoid component compared to THC. In other embodiments THC and CBD or THCV and CBDV are present in approximately equal amounts or THC or THCV are the major component and may be up to 95.5% of the total cannabinoids present.

Particularly preferred embodiments and the target medical conditions for which they are suitable are shown in Table 4 below.

Table 4: Target Therapeutic Groups for Different Ratios of Cannabinoid

Product group	Ratio THC:CBD	Target Therapeutic Area
High THC	>95:5	Cancer pain, migraine, appetite stimulation
Even ratio	50:50	Multiple sclerosis, spinal cord injury, peripheral neuropathy, other neurogenic pain.
Reverse/Broad ratio CBD	<25:75	Rheumatoid arthritis, Inflammatory bowel diseases.
High CBD	<5:95	Psychotic disorders (schizophrenia), Epilepsy & movement disorders Stroke, head injury, Disease modification in RA and other inflammatory conditions Appetite suppression

The pharmaceutical formulations of the invention may be formulated from pure cannabinoids in combination with pharmaceutical carriers and excipients which are well-known to those skilled in the art. For example CBD and THC can be purchased from Sigma-Aldrich Company Ltd, Fancy Road, Poole Dorset, BH12 4QH. CBDV and THCV may be extracted from Cannabis plants using techniques well-known to those skilled in the art. Working with Cannabis plants and cannabinoids may require a government licence in some territories but governments readily make such licences available to parties who apply for the purposes of

medicinal research and commercial development of medicines. In the UK a licence may be obtained from the Home Office.

In preferred embodiments of the invention the formulations comprise extracts of one or more varieties of whole Cannabis plants, particularly Cannabis sativa, Cannabis indica or plants which are the result of genetic crosses, self-crosses or hybrids thereof. The precise cannabinoid content of any particular cannabis variety may be qualitatively and quantitatively determined using methods well known to those skilled in the art, such as TLC or HPLC. Thus, one may chose a Cannabis variety from which to prepare an extract which will produce the desired ratio of CBD to THC or CBDV to THCV or THCV to THC. Alternatively, extracts from two of more different varieties may be mixed or blended to produce a material with the preferred cannabinoid ratio for formulating into a pharmaceutical formulation.

The preparation of convenient ratios of THC- and CBD-containing medicines is made possible by the cultivation of specific chemovars of cannabis. These chemovars (plants distinguished by the cannabinoids produced, rather than the morphological characteristics of the plant) can be been bred by a variety of plant breeding techniques which will be familiar to a person skilled in the art. Propagation of the plants by cuttings for production material ensures that the genotype is fixed and that each crop of plants contains the cannabinoids in substantially the same ratio.

Furthermore, it has been found that by a process of horticultural selection, other chemovars expressing their cannabinoid content as predominantly

tetrahydrocannabinovarin (THCV) or cannabidivarin (CBDV) can also be achieved.

Horticulturally, it is convenient to grow chemovars producing THC, THCV, CBD and CBDV as the predominant cannabinoid from cuttings. This ensures that the genotype in each crop is identical and the qualitative formulation (the proportion of each cannabinoid in the biomass) is the same. From these chemovars, extracts can be prepared by the similar method of extraction. Convenient methods of preparing primary extracts include maceration, percolation, extraction with solvents such as C1 to C5 alcohols (ethanol), Norflurane (HFA134a), HFA227 and liquid carbon dioxide under pressure. The primary extract may be further purified for example by supercritical or subcritical extraction, vaporisation and chromatography. When solvents such as those listed above are used, the resultant extract contains non-specific lipid-soluble material. This can be removed by a variety of processes including chilling to -20°C followed by filtration to remove waxy ballast, extraction with liquid carbon dioxide and by distillation. Preferred plant cultivation and extract preparation methods are shown in the Examples. The resulting extract is suitable for incorporation into pharmaceutical preparations. Methods of administration may be based on sublingual drops, sublingual tablets, gels and sprays, aerosol inhalations, vaporisers, other conventional pharmaceutical oral dosage forms, enemas and rectal suppositories. Other possible formulations are recited in the accompanying claims. Most preferably, the extracts may be formulated into self-emulsifying formulations according to the first and second aspects of the present invention.

There are advantages and disadvantages attached to each of these routes of administration. In general, preparations administered via the respiratory tract, oral/nasal tract and the distal rectum avoid the hepatic first pass effect. Medicaments swallowed are subject to substantial metabolism during their first pass through the liver, and the pattern of metabolites produced may vary according to the route of administration.

There are a number of therapeutic conditions which may be treated effectively by cannabis. The proportion of different cannabinoids in such preparations determines the specific therapeutic conditions which are best treated, and the present invention addresses the formulations which are most suitable for this purpose. As aforesaid the teaching of the invention is illustrated by the use of preparations containing specific ratios of cannabinoid (Table 4), and is further illustrated by the examples.

By direct experiment, it has been shown that administration of CBD (or CBDV) before the administration of THC modifies the cognitive effects experienced. The psychoactive effects of THC are diminished, and subsequent sedation is postponed and mitigated. This reduction is not observed if the THC is given before CBD. Accordingly, one preferred embodiment of the invention is a tablet for buccal or sublingual administration that has a rapidly soluble layer of CBD or CBDV, and a second layer or core of less rapidly soluble THC or THCV. The formulation thus provides a means of making medicaments available for absorption in a timed sequence. Indeed a variety of formulations having modified release profiles which comprise at least two phases can be formulated.

It is a further observation of the present applicants that CBD is able to act as a pharmaceutical stabilizer of pharmaceutical formulations and thus prolong shelf-life. Without being bound by theory it is thought that this may be due to anti-oxidant properties of CBD. Although its anti-oxidant properties are known to be useful in a pharmacological setting in relation to living matter, its effects as a pharmaceutical stabilizer have not previously been observed.

Accordingly, in another of its aspects the invention relates to the use of CBD to extend the shelf-life of a pharmaceutical product which comprises one or more biologically active components. Preferred biologically active components are set forth in the accompanying claims and may be one or more of the classes of medicaments and specific medicaments shown in Table 1 above.

The invention will be further understood with reference to the following examples, together with the accompanying Figures in which:

Figure 1 schematically illustrates the packaging of one example of a dosage form according to the invention. (a) cross section at A-A, (b) sealed product in foil packaging, (c) perforation, (d) opened pack, (e) product ready for use.

Figure 2 schematically illustrates the application of a dosage form according to the invention to the maxillary fossa.

Figure 3 schematically illustrates the dosage form in place.

Figure 4 schematically illustrates typical staining of the mucosa which would be observed after the dosage form has been in place for a period of 1 minute.

Figure 5 is a sample HPLC chromatogram for CBD herbal drug extract.

Figure 6 is a sample HPLC chromatogram for THC herbal drug extract.

Example 1

A 10% solution of pre-gelatinised starch (Component A) is made by dispersing one part of powdered pre-gelatinised starch in 9 parts of water, heating until gelatinised and then cooling. Pre-gelatinised cornstarch is the subject of a monograph in the US National Formulary. This product is used as a component of other formulations given in later examples, and is referred to as "starch gel". It has a negative surface charge.

Example 2

There follows a description of the preparation of a formulation according to the invention in which hop extract, which is an oily resinous material, is used as a surrogate active ingredient. It has a bitter taste and this allows the patient to discern immediately when the active ingredient has stimulated the taste buds, and by implication has interacted with the mucosae. The dispersion of the formulation over the buccal and sublingual mucosae is revealed by the spread of colour. Any increased desire on the part of the patient to swallow the formulation can also be measured by direct observation.

In this example, a formulation is made by

bringing together a gel (containing at least one active component which has a negative surface charge) together with a gel of opposing surface charge. The gel of opposing surface charge may contain optionally at least one active component which may be the same as that in the gel of opposite charge or another active ingredient. When the gels of opposing surface charge are brought together coacervation occurs resulting in a change in viscosity although the resulting gel is still thermoplastic and capable of being dispensed into moulds. On cooling the gel sets into a flexible but rigid gel.

Glycogelatin is prepared by heating bovine or porcine gelatine, or fish gelatine (isinglass) 18 parts and glycerol 2 parts on a water bath with distilled water sufficient to produce a final weight of 100 parts by weight. The glycogelatin so produced is a clear, rigid gel which surprisingly is inherently stable. It is resistant to microbial attack and is in equilibrium with air at a relative humidity of 60-70%.

A formulation is prepared from:

Glyceryl monostearate (SE)	5 parts
Soy lecithin	7 parts
Chlorophyll (oil-soluble)	3 parts
Component A	30 parts
a-Tocopherol BP	0.1 part
Extract of hops	10 parts
Glycogelatin to produce	100 parts

The mixture is heated, with stirring to a temperature of 90°C (using a water bath or in a microwave oven). The mixture is thoroughly stirred and while still molten 2g aliquots are dispensed into aluminium foil moulds which have been treated with a releasing agent. A range of releasing agents is

suitable for this purpose; a solution of silicone or beeswax in normal hexane is sprayed onto the concave mould, and the solvent allowed to evaporate. The weight of finished product can be varied to accommodate quantities of cannabis extract up to approximately 250mg per piece representing a content of approximately 150mg of THC or CBD.

When cool, a foil laminate is placed over the mould and sealed by the application of heat. Evacuation of air and replacement with nitrogen is carried out before final sealing so that the small, residual space in the finished dose unit is an inert, non-oxidising atmosphere.

The product so formed is a lenticular ovate gel which has one convex surface and one plain surface. It contains a colouring agent which is oil soluble and indicates the pattern of distribution of emulsion over the buccal cavity. Incorporation of chlorophyll as a disclosing agent is an optional feature; where used it indicates the areas of buccal mucosae to which a product containing medicament would also spread. These features of the invention are illustrated in Figures 1-4. It will be clear to a person skilled in the art that variations in the emulsifiers and the physical shape and form of packaging are within the teaching of the invention.

Example 3

The formulation described above produces a product which is an elastic but rigid gel. When half of the tablet is placed between the upper jaw and the inside of the mouth (maxillary fossa) on either side, it starts to melt within one minute and at two minutes has produced an emulsified mass which covers the buccal mucosae. The gel does not produce a

discernible sensation when placed between the maxilla and buccal mucosae, and does not induce a desire on the part of the subject to swallow the preparation. The area of buccal mucosae which is covered can be demonstrated by a photographic record taken before, one minute, two minutes, five minutes and 10 minutes, or other convenient time interval after the dosing.

This formulation has a slight taste characteristic of chlorophyll and extract of hops which was discernible for up to 10 minutes after placing the gel in situ, and thus demonstrates the presence of "released medicament" in the oropharynx over this period of time.

The distribution of colour (within one minute, and the persistence of taste for up to 10 minutes) indicates that this type of formulation is suitable as a vehicle for administration of highly lipid soluble medicaments such as cannabis extract or cannabinoids. As formulated, it can be used as a self-indicating placebo preparation in clinical trials. The accompanying Figures illustrate the distribution of one half of a product placed in the mouth. The configuration of the product, and the area of distribution of the product when emulsified in situ is shown in Figures 1-4. Figure 3 shows the position in which the device is originally placed. For clarity of demonstration, the illustration shows the product placed on one side of the mouth. However, it may be divided and placed bilaterally to ensure maximal distribution. Alternatively, products containing different active ingredients can be placed simultaneously, but on separate sides of the mouth.

Example 4

The device described in Example 1 is clamped between two pieces of nylon mesh and attached to the basket of tablet disintegration equipment (BP design)

at a temperature of 35°C. The gel dispersed within 1-2 minutes to produce a fine even-textured emulsion.

Example 5

This Example relates to the preparation of a dosage form containing a mixture of extracts of cannabis. The extracts of cannabis are referred to as Cannabis Based Medicine Extract (CBME) for ease of reference. An extract from a chemovar of cannabis producing more than 90% of its total cannabinoid as cannabidiol (CBD) may be prepared by supercritical fluid extraction of dried cannabis herb. This is referred to as CBME-G5. Similarly, an extract with a high proportion (more than 95%) total cannabinoid as tetrahydrocannabinol (THC) is referred to as CBME-G1. The formula in this example can be varied to accommodate CBME with greater or lesser content of cannabinoids, in order to achieve the desired ratio of THC to CBD, and other cannabinoids. Products containing different ratios of THC to CBD are useful for treatment of specific therapeutic conditions.

A mixture is produced by melting together the following ingredients:

Glyceryl mono-oleate	10 parts
Soy lecithin	10 parts
Curcumin	0.1 part
Component A	20 parts
CBME - G5 to give CBD	1 part
CBME - G1 to give THC	2 parts
α-Tocopherol	0.1 part
Ascorbyl palmitate BP	0.1 part
Glycogelatin to produce	100 parts

The components are mixed with gentle heat on a water bath, stirred and poured while hot into moulds.

The product in moulds is finished as described in Example 1 and sealed under an atmosphere of inert gas.

In this formulation the curcumin imparts a bright yellow colour which allows the area of distribution of the product in the mouth to be identified. α-Tocopherol and ascorbyl palmitate are antioxidants which together with glyceryl mono oleate provide an effective antioxidant system.

The relatively large size (1-2g) of this dosage form allows a comparatively large amount of active ingredient to be incorporated in the dosage form. Cannabidiol may be given in doses of 900mg/day and the dosage form described allows this dose to be given in 2-9 (and preferably 2-4) divided doses per day.

Tetrahydrocannabinol is more active w/w than cannabidiol, and where a smaller unit dose of THC may be required it is possible to include this dose in a sublingual tablet of conventional size. Example 6 illustrates the formulation of such a tablet.

Example 6

Glyceryl monostearate (self emulsifying grade)	5 parts
Polysorbate 80	0.5 parts
Lactose (direct compression grade)	79.3 parts
Soluble starch	10 parts
Tetrahydrocannabinol	5 parts
Ascorbyl Palmitate	0.1 part
α-Tocopherol	0.1 part
Ethanol (dehydrated) BP	10 parts

The GMS, polysorbate, ascorbylpalmitate, a-Tocopherol and THC are dispersed and dissolved in the alcohol. The alcoholic solution is sprayed onto the dry powder ingredients which have been thoroughly mixed. Ethanol

is allowed to evaporate and the granules are dusted with 1% of talc and compressed to a target tablet weight of 101mg in a conventional tablet press. Biconvex punches with a diameter of 7mm or 9mm produce tablets with a high surface/weight ratio. These absorb water when placed in contact with the sublingual or buccal mucosae. The rate of dissolution can be adjusted by altering the degree of compression. Tablets compressed to a pressure of 1-3 Newtons give tablets which disperse in a period of 0.5 - 5 minutes. The disintegration is determined by the method described in Example 4, and for these tablets was less than four minutes.

Example 7

The generation of an emulsion from a self-emulsifying formulation is not limited to solid dosage forms. In the following example three liquid formulations suitable for sublingual application are exemplified. A solution is produced by melting together (at a temperature not exceeding 50°C) the following ingredients (amounts given in parts by weight):-

	A	B	C
Glyceryl mono-oleate (self-emulsifying)	2	2	2
Medium chain triglycerides	5	-	-
Cremophor RH40	30	26.5	-
CBME	10	10	
CBME-G1 to give THC			5
CBME-G5 to give CBD			5
α-Tocopherol	0.1	-	-
Ascorbyl palmitate	0.1	-	-

	A	B	C
Propylene glycol	-	-	44
Ethanol BP	52.8	61.5	44
TOTAL	100	100	100

The products formed by mixing these ingredients are dispensed in 10ml quantities into a glass vial and closed with a pump action spray break-up button. Each 1ml of product contains 100mg of THC and each actuation of the pump delivers a fine spray which can be directed to the area of mucosae under the tongue.

Solutions of CBME in ethanol alone are not generally suitable to be used as a spray. The aggressive nature of pure ethanol as a solvent further limits the amount which can be applied to the mucosae without producing discomfort to the patient. Surprisingly, the addition of a self-emulsifying primary surfactant and solubiliser allows a greater quantity of cannabinoid to be contained in a unit dose. Spraying small quantities onto the sublingual or buccal mucosae results in evaporation of a significant amount of ethanol, and the emulsion so produced is non-irritant and does not stimulate the swallowing reflex. This provides greater dwell time for the in situ-formed emulsion to be in contact with the sublingual or buccal mucosae. A particular feature of this formulation is the accessory solvent activity of the medium chain triglycerides which also act as a secondary emulsifier.

Formulation "B" as listed above has a viscosity within the range of 100-350 centipoises.

Example 8

The solid dosage form may be a soft gelatin capsule, which can be crushed to release the medicament to give an emulsion. The capsule can then be swallowed to provide the residue of the dose for absorption in the remainder of the gastrointestinal tract. The soft gelatin capsule provides an emulsified form of medicament which can be absorbed from any part of the GI tract. A capsule mass may be made from the following ingredients:-

Glyceryl monostearate (self emulsifying)	5 parts
Polysorbate 80	1 part
Beeswax	5 parts
CBME G1 to give THC	10 parts
CBME G5 to give CBD	10 parts
α-tocopherol	0.1 part
Ascorbyl palmitate	0.1 part
Hemp oil to produce	100 parts by weight

Example 9

A dosage form for buccal use which uses vegetable rather than animal gelling agents may be made as follows:

Sorbitol	35 parts
Gum Acacia	20 parts
Glyceryl mono-oleate	10 parts
Egg lecithin	10 parts
CBME-1 to produce 5 mg THC	5 parts
CBME-5 to produce 5 mg CBD	5 parts
Tocopherol	0.1 parts
Ascorbyl palmitate	0.1 parts
Vanillin	0.1 parts
BHT	0.01 parts

Glycerol	5.0 parts
Water	qs

The fat soluble ingredients are melted together at a temperature of 70°C. Sorbitol is mixed with the Acacia gum, dispersed in glycerol, and added to the other solid ingredients. Water is added, and the mass heated on a boiling water bath until evenly dispersed/dissolved. While still at a temperature of 60°C the mass is distributed into moulds (as described in Example 1). The mass can also be cast or rolled into a sheet, preferably 2.5mm thick. Oval or hexagon-shaped pieces with an area of 40mm^2 are cut and the pieces applied to a non-stick backing sheet larger than the piece, and covered with a non adhesive protective membrane. The patch so formed is sealed under an inert gas blanket into a pocket formed from heat-sealable foil laminate. The product so produced is suitable for treatment of patients suffering from migraine, arthritis, epilepsy, multiple sclerosis and other types of neuropathic and neurogenic pain, where it is necessary to have release of the medicament over a period of hours. Disintegration time for this formulation is greater than 90 minutes.

Example 10

A product providing fast release of a constituent and a further release of constituent over a prolonged time can be produced by making a combination dose unit. Using the formulation described in Example 8, a quantity of heated mass is filled into a mould or cast into a film, and allowed to set. A layer of material as described in Example 5 is then cast onto the surface of the gel described in Example 9. The composite gel is then packaged as described in these examples. Variation of the proportions of mass in the two layers provides for modification of the kinetic

profile produced by the dose unit.

In some circumstances it may be desirable to administer two drugs in a time dependent order. This can arise where one drug of the pair has a protective effect on the other. Example 10 describes a composite gel formulation of the type described in earlier examples. The formulation described in Example 11 provides CBD which is an antioxidant known to have a protective effect on THC to be made available for absorption through the buccal/sublingual mucosae just before THC. Cannabidiol is contained in the fast release layer and THC is dissolved out of the delayed release layer. Example 11 describes a dose unit consisting of two layers with differing dissolution characteristics.

Example 11

(a)	Glyceryl mono-oleate	7 parts
	Soy lecithin	7 parts
	Acacia gum	15 parts
	Tetrahydrocannabinol	10 parts
	α-tocopherol	0.1 parts
	Xylitol	5.1 parts
	Glycerol	3 parts
	Purified Water	to produce 100 parts

A molten mass is prepared as described in previous examples and aliquots cast into moulds or as a sheet.

(b)	Glyceryl mono-oleate	15 parts
	Soy lecithin	10 parts
	Component A	20 parts
	α-tocopherol	0.1 parts
	Cannabidiol	20 parts
	Glycogelatin to produce	100 parts

A mass is prepared as described in Example 2. The mass is cast as a second layer into a mould containing an aliquot of formulation (a). At the interface there is slight melting and bonding of the two components to give a coherent product. If the gel is cast into a concave mould, the product has a planar surface which, if placed in contact with the mucosa is the first to disperse and thus produces the required sequence of presentation of components for absorption.

A layer of formulation (b) can be cast on the surface of a sheet of formulation (a). The two formulations contain colloidal components with opposing signs and at the zone of fusion good adhesion is produced by coacervation. The composite layer is then cut into shapes suitable for application to the oral mucosae. The product is packed as described in Example 3 and protected from air and light.

Example 12

The following examples illustrate the distinctive features of formulations intended for spray application to the buccal mucosae, the method of application, and the blood levels produced by buccal absorption in comparison with sublingual administration.

The following are examples of a liquid formulations suitable for buccal administration. A solution is produced by dissolving (at a temperature not exceeding 50°C) the following ingredients (quantitative details are expressed as parts by weight):-

are used. CBME-G1 is an extract from a high THC-yielding strain of cannabis, and CBME-G5 is from a high CBD-yielding variety. It will be clear to a person skilled in the art that purified cannabinoids, and extracts containing the cannabinoids, can be made formulated as described above by quantitative adjustment.

Although solutions of CBME in ethanol alone can be used as a spray, the quantity of cannabinoid that can be delivered is limited by the aggressive nature of pure ethanol in high concentration as a solvent. This limits the amount that can be applied to the mucosae without producing discomfort to the patient. When a group of patients received THC or CBD in a solution of the type described above, directing the spray either sublingually or against the buccal mucosa, the patients uniformly reported a stinging sensation with the sublingual application, but mild or no discomfort when the same solution was sprayed onto the buccal mucosa. It was further, surprisingly, found that the addition of a self-emulsifying primary surfactant as solubiliser allowed a greater quantity of cannabinoid to be contained in a unit dose. Spraying small quantities of this type of formulation onto the buccal mucosa does not appreciably stimulate the swallowing reflex. This provides greater dwell time for emulsion formed in situ to be in contact with the buccal surface.

Formulations were administered to a group of 13 human subjects so that they received 4mg THC, 4mg of CBD or placebo (vehicle alone) via a sublingual

tablet, sublingual pump-action spray or buccal route.

Absorption [area under the absorption curve (AUC)] of cannabinoid and primary metabolite were determined in samples of blood taken after dosing. The following Table 5 gives these as normalised mean values.

Table 5

	Route of Administration		
Analyte in Plasma	PAS sublingual	Sublingual tablet	Oropharyngeal
	AUC	AUC	AUC
THC	2158.1	1648.4	1575.0
11 OH THC	3097.8	3560.5	2601.1
CBD	912.0	886.1	858.0

These results show that the total amounts of cannabinoid absorbed by sublingual and buccal (oropharyngeal) routes are similar but that there is a substantial (approximately 25%) reduction in the amount of 11 OH metabolite detected after oropharyngeal (buccal) administration. This finding is not inconsistent with reduced swallowing (and subsequent reduced hepatic) metabolism of the buccal formulation.

It is known that 11-hydroxy metabolite of THC is possibly more psychoactive than the parent compound. It is therefore desirable to minimise the amount of this metabolite during administration, and this is likely to be achieved by using a formulation and method of application which reduces the amount of a buccal or sublingual dose that is swallowed. The pump

action spray appears to offer a simple means of reducing the amount of material that is swallowed and metabolised by absorption from the intestinal tract below the level of the oropharynx.

Example 13

The use of a pump action dispenser makes it possible to dispense defined quantities of a gel with the required precision and repeatability for pharmaceutical applications. A gel is prepared from the following ingredients (parts by weight):-

Carboxymethylcellulose Sodium	2
Glyceryl monostearate	10
Glycerol	10
CBME-G1 and G5 to give THC and CBD	5
Ethanol	40
Ascorbic Acid	0.1
Tocopherol	0.1
Water to	100

The non-aqueous ingredients are melted together at a temperature of not more than 50°C until evenly suspended. Water is then added to produce a viscous creamy gel, taking care not to introduce air during mixing. The product is dispensed into containers whilst still warm and sealed with a pump dispenser head (type 251/331) supplied by Valois. The head on this device delivers a ribbon of gel, and when pressure is removed, there is sufficient retraction of gel to ensure that particles of gel are not left exposed. The quantity of gel can be directed to accessible buccal surfaces, where it adheres. When the buccal surface returns to its normal position the mass of gel then absorbs more water

from the available saliva and yields its charge of medicament.

Example 14

Experiments have shown the effect of varying the amount of self-emulsifier and proportions of negative and positively charged viscolising agents on dissolution/disintegration time in the mouth.

Solid gel formulations as described in Examples 1 and 2 were prepared by dissolving the ingredients by heating in a microwave oven, until a uniform molten mass was produced. The molten mass was dispensed using a Gilson-type pipette directly into recycled blisters, which had been washed with 70% alcohol and air dried. Disintegration time was measured in a BP type apparatus.

The effects are described below:-

Disintegration time increases with increased mass:-

	G001/A (i)	G001/A(ii)	G001(iii)
Mass (mg)	586	807	2140
T_{dis} (m,s)	920	1230	2110

Increasing emulsifier content increases T_{dis}:-

	G001A	G001B
% emuls	10	20
T_{dis}	1345	8730

Increasing gelatin content of gel has little effect on T_{dis}:-

	G001/A	G001/B
Mass (mg)	1145	807
% gelatin	14	25
T_{dis}	1345	1230

Addition of pre-gelatinised maize starch (PGMS) decreases T_{dis}:-

	G002/A(ii)	G003
Mass (mg)	807	751
% PGMS	0	2
T_{dis}	920	405

Example 15 Growing of Medicinal Cannabis

Plants are grown as clones from germinated seed, under glass at a temperature of 25°C ± 1.5°C for 3 weeks in 24 hour daylight; this keeps the plants in a vegetative state. Flowering is induced by exposure to 12 hour day length for 8-9 weeks.

No artificial pesticides, herbicides, insecticides or fumigants are used. Plants are grown organically, with biological control of insect pests.

The essential steps in production from seed accession to dried Medicinal Cannabis are summarised as follows:

Seed Accessions

↓

Seeds germinated at G-Pharm (UK)

↓

Selection for cannabinoid content and vigour

↓

Mother Plant

↓

Cuttings rooted

14-21 days in peat plug

25 C, 24 hour day length

↓

Rooted cuttings potted up in 5 litre pots of bespoke compost

↓

Young Clone Plant established

3 weeks, 24 hour day length, 25 °C

↓

Lower Branches Removed end of week 3

Used to make new generation of cuttings

↓

Induction of flowering

Plant relocation to 12 hour day length are to induce flowering

↓

Flower formation and maturation

8-9 weeks at 25 °C

↓

Harvest

90% of flowers and leaves senesced

↓

Drying

Under conditions of light exclusion

↓

MEDICINAL CANNABIS

Example 16 Determination of Cannabinoid Content in Plants and Extracts

Identity by TLC

a) Materials and methods

Equipment Application device capable of delivering an accurately controlled volume of solution i.e

1 µl capillary pipette or micro litre syringe.

TLC development tank with lid

Hot air blower

Silica gel G TLC plates (SIL N-HR/UV254), 200 µm layer with fluorescent indicator on polyester support.

Dipping tank for visualisation reagent.

Mobile phase	80% petroleum ether 60:80/20% Diethyl ether.
Visualisation reagent	0.1% w/v aqueous Fast Blue B (100mg in 100ml de-ionised water). An optional method is to scan at UV 254 and 365 nm.

b) Sample preparation

i) Herbal raw material

Approximately 200mg of finely ground, dried cannabis is weighed into a 10ml volumetric flask. Make up to volume using methanol:chloroform (9:1) extraction solvent.

Extract by ultrasound for 15 minutes. Decant supernatant and use directly for chromatography.

ii) Herbal drug Extract

Approximately 50mg of extract is weighed into a 25ml volumetric flask. Make up to volume using methanol solvent. Shake vigorously to dissolve and then use directly for chromatography.

c) Standards

0.1 mg/ml delta-9-THC in methanol.
0.1mg/ml CBD in methanol.

The standard solutions are stored frozen at -20°C between uses and are used for up to 12 months after initial preparation.

d) Test solutions and method

Apply to points separated by a minimum of 10mm.

i) either 5 µl of herb extract or 1 µl of herbal extract solution as appropriate,
ii) 10 µl of 0.1 mg/ml delta-9-THC in methanol standard solution,
iii) 10 µl of 0.1mg/ml CBD in methanol standard solution.

Elute the TLC plate through a distance of 8cm, then remove the plate. Allow solvent to evaporate from the plate and then repeat the elution for a second time (double development).

The plate is briefly immersed in the Fast Blue B reagent until the characteristic re/orange colour

of cannabinoids begins to develop. The plate is removed and allowed to dry under ambient conditions in the dark.

A permanent record of the result is made either by reproduction of the image by digital scanner(preferred option) or by noting spot positions and colours on a tracing paper.

Assay THC, THCA, CBD, CBDA and CBN by HPLC

a) Materials and methods

Equipment:	HP 1100 HPLC with diode array detector and autosampler. The equipment is set up and operated in accordance with in-house standard operating procedures (SOPlab037)
HPLC column	Discovery C8 5 µm, 15x 0.46 cm plus Kingsorb ODS2 precolumn 5 µm 3 x 0.46 cm.
Mobile Phase	Acetonotrile:methanol:0.25% aqueous acetic acid (16:7:6 by volume)
Column Operating Temperature	25°C
Flow Rate	1.0 ml/min
Injection Volume	10 µl
Run time	25mins

Detection	Neutral and acid cannabinoids 220nm (band width 16nm) Reference wavelength 400nm/bandwidth 16nm Slit 4nm Acid cannabinoids are routinely monitored at 310nm (band width 16nm) for qualitative confirmatory and identification purposes only.
Data capture	HP Chemistation with Version A7.01 software

b) Sample preparation

Approximately 40mg of Cannabis Based Medicinal Extract is dissolved in 25ml methanol and this solution is diluted to 1 to 10 in methanol. This dilution is used for chromatography.

0.5 ml of the fill solution, contained within the Pump Action Sublingual Spray unit, is sampled by glass pipette. The solution is diluted into a 25ml flask and made to the mark with methanol. 200 µl of this solution is diluted with 800 µl of methanol.

Herb or resin samples are prepared by taking a 100mg sample and treating this

with 5 or 10ml of Methanol/Chloroform (9/1 w/v). The dispersion is sonicated in a sealed tube for 10 minutes, allowed to cool and an aliquot is centrifuged and suitably diluted with methanol prior to chromatography.

c) Standards

External standardisation is used for this method. Dilution of stock standards of THC, CBD and CBN in methanol or ethanol are made to give final working standards of approximately accurately 0.1 mg/ml. The working standards are stored at -20°C and are used for up to 12 months after initial preparation.

Injection of each standard is made in triplicate prior to the injection of any test solution. At suitable intervals during the processing of test solutions, repeat injections of standards are made. In the absence of reliable CBDA and THCA standards, these compounds are analysed using respectively the CBD and THC standard response factors.

The elution order has been determined as CBD, CBDA, CBN, THC and THCA. Other cannabinoids are detected using this method and may be identified and determined as necessary.

d) Test solutions

Diluted test solutions are made up in methanol and should contain analytes in the linear working range of 0.02-0.2 mg/ml.

e) Chromatography Acceptance Criteria:

The following acceptance criteria are applied to the results of each sequence as they have been found to result in adequate resolution of all analytes (including the two most closely eluting analytes CBD and CBDA)

i) Retention time windows for each analyte:

CBD 5.4-5.9 minutes
CBN 7.9-8.7 minutes
THC 9.6-10.6 minutes

ii) Peak shape (symmetry factor according to BP method)

CBD < 1.30
CBN < 1.25
THC < 1.35

iii) A number of modifications to the standard method have been developed to deal with those samples which contain late eluting impurity peaks e.g method CBD2A extends the run time to 50 minutes. All solutions should be clarified by centrifugation before being transferred into autosampler vials sealed with teflon faced septum seal and cap.

iv) The precolumn is critical to the quality of the chromatography and should be changed when the back pressure rises above 71 bar

and/or acceptance criteria regarding retention time and resolution, fall outside their specified limits.

f) Data Processing

Cannabinoids can be subdivided into neutral and acidic- the qualitative identification can be performed using the DAD dual wavelength mode. Acidic cannabinoids absorb strongly in the region of 220nm-310nm. Neutral cannabinoids only absorb strongly in the region of 220nm.

Routinely, only the data recorded at 220 nm is used for quantitative analysis.

The DAD can also be set up to take UV spectral scans of each peak, which can then be stored in a spectral library and used for identification purposes.

Data processing for quantitation utilises batch processing software on the Hewlett Packard Chemstation.

a) Sample Chromatograms

HPLC sample chromatograms for THC and CBD Herbal Drug extracts are provided in the accompanying Figures.

Example 17 Preparation of the Herbal Drug Extract

A flow chart showing the process of manufacture of extract from the High-THC and High-CBD chemovars is given below:

Medicinal Cannabis (High-THC or High-CBD)

↓

Chopping to predominantly 2 to 3mm

↓

Heating at 100 to 150°C for sufficient time to decarboxylate acid form of cannabinoids to produce neutral cannabinoids

↓

Extraction with a specified volume of liquid carbon dioxide over 6 to 8 hours

↓

Removal of CO2 by depressurisation to recover crude extract

↓

"Winterisation"-Dissolution of crude extract in ethanol Ph. Eur. followed by chilling solution (-20°C/48 hrs) to precipitate unwanted waxes

↓

Removal of unwanted waxy material by cold filtration

↓

Removal of ethanol from the filtrate by thin film evaporation under reduced pressure

Example 18

High THC cannabis was grown under glass at a mean temperature of 21 + 2°C, RH 50-60%. Herb was harvested and dried at ambient room temperature at a RH of 40-45% in the dark. When dry, the leaf and flower head were stripped from stem and this dried biomass is referred to as "medicinal cannabis".

Medicinal cannabis was reduced to a coarse powder (particles passing through a 3 mm mesh) and packed into the chamber of a Supercritical Fluid Extractor. Packing density was 0.3 and liquid carbon dioxide at a pressure of 600 bar was passed through the mass at a temperature of 35°C. Supercritical extraction is carried out for 4 hours and the extract was recovered by stepwise decompression into a collection vessel. The resulting green-brown oily resinous extract is further purified. When dissolved in ethanol BP (2 parts) and subjected to a temperature of -20°C for 24 hours a deposit (consisting of fat-soluble, waxy material) was thrown out of solution and was removed by filtration. Solvent was removed at low pressure in a rotary evaporator. The resulting extract is a soft extract which contains approximately 60% THC and approximately 6% of other cannabinoids of which 1-2 % is cannabidiol and the remainder is minor cannabinoids including cannabinol. Quantitative yield was 9% w/w based on weight of dry medicinal cannabis.

A high CBD chemovar was similarly treated and yielded an extract containing approximately 60% CBD with up to 4% tetrahydrocannabinol, within a total of other cannabinoids of 6% Extracts were made using THCV and CBDV chemovars using the general method described above.

A person skilled in the art will appreciate that other combinations of temperature and pressure (in the range +10°C to 35°C and 60 - 600 bar) can be used to prepare extracts under supercritical and subcritical conditions.

Example 19

Street cannabis (marijuana) grown in the US and Caribbean typically has a high percentage of total cannabinoid as THC; European (usually described as "Moroccan" cannabis) contains approximately equal quantities of THC and CBD. This may account for conflicting reports on the efficacy of cannabis in certain clinical studies. The applicant has sought to introduce precision in producing defined ratios of cannabinoid in two ways; by using mixtures of defined extracts and also by producing an extract from a single chemovar which produces the appropriate ratio of cannabinoids. Chemovars which express their cannabinoid content as predominantly one compound have been used to prepare the formulations of the invention but the teaching of the patent can be applied to synthetically produced cannabinoids or cannabinoids obtained by purification of cannabis

Certain chemovars express an approximately 50:50 ratio of THCV/CBDV. It is therefore convenient to use a single plant extract to provide the ratio of cannabinoids. When the plants are grown from cuttings, the genotype is fixed and the ratio of cannabinoids is a constant. The overall yield may vary but this is factored into the quantity of extract used to provide a defined quantity of cannabinoid. A formulation which is particularly suitable for the treatment of multiple sclerosis is made to the following formula:

CBME extract of chemovar G10 providing

	5a	5b	5c	
THCV	0.1	2.5	10	parts
CBDV	0.1	2.5	10	parts
Spray-dried lactose	60	60	50	parts
Dextrates	37.7	21.5	16.5	parts
Lecithin	1	10	10	parts
α-tocopherol	0.1	2.5	2.5	parts
Magnesium stearate	1	1	1	part

The CBME-G10 extract is dissolved in 5 parts of ethanol and this solution used to mass the other ingredients. The mass is forced through a sieve, and the granules are dried at low temperature. When dry, the granules are dusted with magnesium stearate and compressed to 1.5 Newtons to give tablets suitable for sublingual administration to patients with multiple sclerosis, spinal chord injury, peripheral neuropathy or other neurogenic pain.

Example 20

In order to make cannabidiol available before THC, a multi layered dosage form has been developed. In this exemplification, THC obtained either from synthetic or natural sources is contained in a core. CBD obtained from a natural source such as a cannabis chemovar extract or from synthetic material is present in the outer coating, which dissolves first and is followed by THC.

A two-layered tablet is formulated from the following

ingredients.

Inner Core:

CBME-G1 providing THC	2 parts
Direct compression lactose	66.9 parts
Pre-gelatinised starch	30 parts
α-tocopherol	0.1 part
Magnesium stearate	1 part

The CBME is dissolved in sufficient ethanol for the whole to be sprayed onto the other dry ingredients. The powder is allowed to dry at room temperature and thoroughly mixed. Magnesium stearate is added and the tablets are compressed to a hardness of 6 Newtons. These cores can be pressed conveniently in a tablet press with 7mm biconvex dies. When tested in a BP-type disintegration apparatus, disintegration time of these core tablets was 5 - 10 minutes.

Outer Layer:

The outer layer of tablets was prepared from the following ingredients:

CBME-G5	8 parts
Glycerol monostearate	5 parts
Lecithin	5 parts
Direct compression lactose	55 parts
Pre-gelatinised starch	26.7parts
α-tocopherol	0.2 parts
Oil of Peppermint	0.1 part

Sufficient ethanol BP is used to dissolve the

CBME extract which is then sprayed on to the other dry ingredients. Ethanol is allowed to evaporate at room temperature and the dry granules are thoroughly mixed and tableting arranged so that half of the charge is delivered into a 9mm table die. The charge is lightly compressed (0.25 Newtons), a core as described above is added to each die, and the remainder of the tablet granules added to the die. Tablets are compressed to a hardness of 1.5 Newtons.

The tablets so produced have a soft outer coat which is compressed sufficiently hard to withstand limited handling, and are individually packed in blister packs to reduce friability. When the tablet is placed under the tongue, the soft outer core quickly disintegrates and forms a slightly gelatinous mass which yields CBD. The disintegration of this coating when tested in a BP model disintegration apparatus is 1-4 minutes. The harder core containing THC then dissolves and then yields THC for absorption after CBD has already been presented to the sublingual or buccal mucosae. By using a two-layered tablet in this way it is possible to optimise the sequence of presentation of cannabinoids. CBD absorbed first has an *in vitro* and *in vivo* antioxidant activity which is beneficial in enhancing the stability of THC and aiding its absorption. As the CBD component of the extract used to supply the THC component contains relatively small amounts of CBD which would act as antioxidant, additional tocopherol is included to act as a chemical antioxidant. The tablets so produced are useful in the treatment of multiple sclerosis and other neurogenic pains.

The same tablet mix when compressed to a hardness of 6 Newtons is also suitable for the treatment of rheumatoid arthritis and other inflammatory bowel diseases when given as an oral preparation intended to be swallowed.

Surprisingly, although it is reported that cannabis stimulates appetite, it has been shown by direct experiment that high CBD extracts decrease the food intake and weight gain of mice. The high CBD formulation is therefore useful as a means of reducing appetite in humans.

Example 21

A specific chemovar (designated G9) produces two principal cannabinoids, THCV:THC in the ratio 85:15. This chemovar produces relatively little CBD and this exemplifies the extreme of the high THC:CBD ratios. THCV produces a more rapid analgesic effect than THC, with reduced potential for hangover. A pharmaceutical preparation prepared from this extract is therefore desirable for the treatment of opioid-resistant pain where a rapid onset of action is required. A sublingual spray formulation has the following formula.

CBME-G9 extract providing THCV 85 parts THC 15 parts	
Cremophor RH40	300 parts
α-tocopherol	1 part
Ethanol BP to produce	1,000 parts

The ingredients are dissolved in the ethanol and dispensed in 10ml quantities into a glass vial, closed

with a pump action spray break-up button. Each 1ml of product contains 100mg of cannabinoid, and each actuation of the pump delivers 100 µl in a fine spray which is directed to the area of mucosae under the tongue.

This preparation is used as part of the treatment for patients suffering from migraine, cancer pain and multiple sclerosis.

Example 22

A formulation as described in the preceding example is made up substituting CBME-G5 (high CBD). This spray can be used to prime patients by giving a dose of CBD 5-10 minutes before administration of the high THC/THCV formulation.

Proprietary two-compartment/double pressure buttons are available, and a composite package contains solution as described in this and the preceding example. The availability of the two sublingual solutions in a convenient package allows the patient to titrate the dose of either component to optimise the therapeutic effect required.

The antioxidant effect of CBD *in vitro* is demonstrated by the following assay levels after storage at 5±3°C. The data are reported as percentage of initial assay value.

Table 6: Stability Data for High THC and High CBD and Even Ratio CBD/THC, Pump Action Spray (PAS), and Sublingual Tablets.

FORMULATION	ASSAY VALUE AFTER ELAPSED TIME			
	3 months (range)		6 months (range)	
PASS	THC	CBD	THC	CBD
High THC	98.2 (95.6-100.4)		95.6 (93.7-98.5)	
High CBD		100.6 (99.7-101.6)		101.0 (98.3-103.6)
Even ratio THC:CBD	99.5 (98.3-101.5)	101.2 (100.3-102.0)	100.4 (99.3-102.8)	104.5 (193.5-106.5)
SUBLINGUAL TABLETS STORED AT 5°C				
High THC (2mg)	98.4			
High CBD (2mg)		99.0		
Even ratio	95.5	99.0		

It is clear from the table above that CBD in this formulation has good stability, whereas THC is less stable. A preparation containing both CBD and THC in the concentrations which are of therapeutic interest appears to have a protective action and enhances the stability of the even ratio spray and tablet products.

The examples given above illustrate the teaching of the invention, and it will be clear to one skilled in the art that elements from the different formulations can be adapted to produce a wide range of formulations. These are suitable for treatment of a range of therapeutic indications. Elements may be taken from any of the above examples to produce a specific formulation with the desired speed of onset and duration of action within the limits described.

Example 23

Cannabinoids are known to be useful in the treatment of inflammatory bowel disease. However, the amount of cannabinoid reaching the lower bowel (distal ileum and colon) is unknown. Enemas are suitable for local application of inflamed bowel. The following formulation is based on a foaming enema and provides a broad ratio combination of cannabinoids for local application.

CBME-G1 providing THC	4 mg
CBME-G5 providing CBD	20mg
Docusate sodium	100mg
Glycerol monostearate	2.5gm
Carboxymethylcellulose	250mg
Water	250ml

The CBME extracts are dissolved in the ingredients and mixed in the order indicated above. A 50ml quantity is dispensed into a compressible plastic container fitted with a 150ml enema nozzle with a terminal bulb. Before use, the container is shaken vigorously to produce a foam. The foam is injected by the nozzle and the quantity of foam produced travels typically for 1-2 metres into the lower bowel. The foam is compressible and produces minimal discomfort to the patient compared with non-compressible enemas. The method of treatment can be combined with steroids given either systemically or as an enema for treatment of inflammatory bowel disease.

Example 24

A product as described in Example 10 when placed in the maxillary fosse releases constituent into the

buccal mucosae but also into the saliva present in the mouth. Coating the convex surface of the gel with a material that is less soluble than the substance of the gel will reduce the amount of constituent lost into the saliva and thereby increase the concentration in contact with the buccal mucosae. Formulations as described in Example 10 can be further modified in order to provide a gel in which a coating on the convex (proximal or inward facing surface) of the gel forms an integral part of the product. The added layer retards the dissolution of the gel and for convenience is referred to as a water insoluble layer (WIL). The WIL is a thermo setting gel which dispensed first into the mould at a temperature between 50 - 80°C. Whilst still warm the formulations described in Examples 10 or 11 are then dispensed in the manner and in the order described therein. Dispensing the molten mass while the WIL is still molten causes the WIL to be spread around the concave mould and results in a layer which is on the convex side of the contained, moulded gel.

When tested in the method described in Example 4, the distal portion of the gel dissolves leaving the WIL undissolved.

The WIL may be formed from the following composition in which the concentration of acacia gum in Example 11 is increased to give a more rigid, structural component of the gel.

Glyceryl mono-oleate	5 parts
Soya lecithin	5 parts
Acacia gum	30 parts

Tetrahydrocannabinol	10 parts
α-tocopherol	0.1 parts
Zylitol	3 parts
Glycerol	3 parts
Purified water to produce 100 parts	

The ingredients are mixed as described in Example 11 and heated until dissolved. Aliquots are dispensed into moulds or as a sheet.

The similarity of the formulation in the WIL with the layer described in Example 11 results in a slight degree of mixing at the interface, and bonding of the components to give a coherent product.

The type of cannabinoid and proportion of cannabinoid, which are described in other examples, can be introduced into a multiple layer product as described in this example.

Example 25

A water insoluble layer can also be formed on the gels by, for example, spraying a 5% solution of ethyl cellulose in ethanol on to the inner surface of the mould before introducing the first component described in Example 10. The alcoholic solution is sprayed through a mask, which protects the surface of the mould where it is intended to have an adherent layer of sealing film. The solvent is allowed to evaporate before introducing the gel as described in Example 10. This procedure has the added advantage, should it be needed, of reducing the bioburden on the inner surface of the mould. When mould composition is introduced into the mould it adheres strongly to the ethyl

cellulose and forms the water insoluble layer. Where the medicament is formed by casting layers of material on a plane surface, a 5% solution of ethyl cellulose is sprayed onto the surface. After evaporation of solvent, the composite layer as described in Example 10 is formed thereon.

REFERENCES

Adams M.D. *et al* (1977)
A Cannabinoid with Cardiovascular Activity but no Overt Behavioural Effects
Experientia, **33**, 1204-1205

Burstein S. and Raz A. (1972)
Inhibition of prostaglandin E2 biosynthesis by D1-tetrahydrocannabinol. Prostaglandins 2 :369-375.

Ed. Brown D.T, 207
Cannabis 'The Genus *Cannabis*'

Carlini E.A., Leiter J.R., Tannhauser M. and Berardi A.C. (1973) Cannabidiol and *Cannabis sativa* Extract Protect Mice and Rats Against Convulsive Agents
J. Pharm. Pharmacol **25**, 664-665

Davis K H Jr., McDaniel I A Jr., et al
Some Smoking Characteristics of Marijuana Cigarettes.
The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects
Academic Press, Inc. (1984)

De Meijer E.P.M. and Keizer L.C.P. (1996)
Patterns of diversity in *Cannabis*. *Genetic Resources and Crop Evolution*, **43**, 41-52

Guy G W, Whittle B A and Grey MJ
Dose dispensing Apparatus
GB Pat Application 25809.5, Oct 20, 2000

Guy G W, Whittle B A and Grey M J
Secure dispensing of materials
GB Patent Application 25811.1, Oct 20, 2000

Hampson A.J., Grimaldi M., Axelrod J. and Wink D.
(1998)
Cannabidiol and (-) 9-Tetrahydrocannabinol are
Neuroprotective Antioxidants
Proc. Nat. Acad. Sci. **95**, 8268-8273

Hardy *et al*
Respiratory Medicine (1993) **87**: 461-465

House of Lords Science and Technology Sub Committee
report
The Development of Prescription Cannabis-Based
Medicines (Jan 2001)

In-house Report GPA 002/000159
CBD Primary Screening Program (2000)

Iversen L.L.
The Science of Marijuana, Oxford University Press,
48-49 (2000)

Mechoulam R ed.
Cannabinoids as Therapeutic Agents, CRC Press, Boca
Raton,FL, New York (1976)

Merck Index, 12th Edition, (1996) #1792

Merck's Manual (1899), Part 1, pg 26.

Pate D. US Patent Application Number 08/919317, 28 August 1997

Pertwee R.G. (1998)
Advances in Cannabinoid Receptor Pharmacology in Cannabis
The Genus Cannabis (Ed. Brown D.T.) Harwood Publishers, 125-174

Petro D.J. (1980)
Marijuana as a Therapeutic Agent for Muscle Spasm or Spasticity
Psychosomatics 21(1), 81-85

Price M A P, and Notcutt W G
Cannabis in Pain Relief
In Cannabis : The Genus Cannabis (Ed Brown D T)
Harwood Publishers, 223 - 246

Raman A.
The Cannabis Plant: Cultivation and Processing for Use
In Cannabis: the genus *Cannabis*, 29 - 54, Ed Brown D T

Ram and Sett (1982) Zeitschrift fur pflanzenphysiologie, 107(1), 85-89

Samuelsson G
Drugs of Natural Origin 155-160Swedish Pharmaceutical Press, Stockholm, Sweden,

Smiley K.A., Karber R. and Turkanis S.A. (1976)
Effect of Cannabinoids on the Perfussed Rat Heart
Res. Comm. Chem. Pathol. Pharmacol, 14, 659-673

Tashkin D P, Shapiro B J, and Frank I M

Acute pulmonary and physiological effects of smoked marijuana and oral delta-9-THC in healthy young men N Eng J Med, **289**, 336-341

Touitou E
US Patent 5,540,934 (July 30, 1996)

Touitou E, Fabin B, Danny S and Almog S
Transdermal Delivery of Tetrahydrocannabinol
Int. J. of Pharmaceutics (1988) **43**: 9-15

Whittle B A and Guy G W
Formulations for sublingual delivery
GB Patent Application 103638.3, Feb 14, 2001

Zuardi A.W. and Guimares F.S. (1991)
Cannabidiol as an Anxiolytic and Antipsychotic in Cannabis: The Medicine Plant
McFarland & Co, London: 133-141

CLAIMS:

1. A pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, which formulation comprises at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament.

2. A formulation according to claim 1 which is not in the form of a propellant-driven aerosol or a propellant-driven liquid spray.

3. A formulation according to claim 1 or claim 2 which further comprises one or more viscolising agents.

4. A formulation according to claim 3 wherein the viscolising agent(s) is/are not block copolymers of oxyethylene and oxypropylene.

5. A formulation according to claim 3 wherein the viscolising agent(s) is/are not nonionic surfactants.

6. A formulation according to claim 5 which comprises at least one viscolising agent that when hydrated forms a gel having positive surface electrical charge and at least one viscolising agent that when hydrated forms a gel having negative surface electrical charge..

7. A formulation according to claim 6 which comprises at least one viscolising agent that when hydrated forms a gel having positive surface electrical charge which is gelatin or glycogelatin and at least one viscolising agent that when hydrated forms a gel having negative surface electrical charge which is starch, pre-gelatinised starch, acacia or polydextrose.

8. A formulation according to any one of claims 3 to 7 wherein at least one of the viscolising agents is solubilised by the action of an enzyme present in saliva.

9. A formulation according to any one of the preceding claims which is a solid dosage form, preferably a gel, compressed tablet or capsule.

10. A formulation according to claim 9 which is in the form of a gel for administration of a lipophilic medicament via the sublingual and/or buccal mucosae, wherein on contact with saliva the gel or gel-spray forms an emulsion containing the lipophilic medicament that adheres to the sublingual and/or buccal mucosae.

11. A formulation according to claim 9 which is in the form of a compressed tablet for administration of a lipophilic medicament via the sublingual and/or buccal mucosae, wherein on contact with saliva the tablet disintegrates completely and forms an emulsion containing the lipophilic medicament that adheres reversibly to the sublingual and/or buccal mucosae.

12. A formulation according to any one of claims 9 to 11 wherein the total amount of viscolising agent(s) included in the formulation is greater than 60% w/w of the formulation.

13. A formulation according to any one of claims 9 to 11 wherein the self-emulsifying agent(s) is/are present in an amount at least 5% w/w, preferably at least 10% w/w of the formulation.

14. A formulation according to claim 1 or claim 2 which further contains at least one solvent.

15. A formulation according to claim 1 or claim 2 which further contains at least one co-solvent.

16. A formulation according to claim 15 wherein the co-solvent is a solubilising agent.

17. A formulation according to claim 16 wherein the solubilising agent is a polyoxyethylene castor oil derivative.

18. A formulation according to claim 17 wherein the polyoxyethylene castor oil derivative is cremophor, preferably cremophor RH40.

19. A formulation according to any one of claims 14 to 18 which is a gel-spray.

20. A formulation according to claim 19 which is in the form of a gel-spray for administration of a lipophilic medicament via the sublingual and/or buccal mucosae, wherein on contact with saliva the gel or

gel-spray forms an emulsion containing the lipophilic medicament that adheres to the sublingual and/or buccal mucosae.

21. A formulation according to any one of claims 14 to 20 which further contains one or more viscolising agents, wherein the total amount of viscolising agent(s) included in the formulation is at least 1% w/w of the formulation.

22. A formulation according to any one of claims 14 to 21 wherein the self-emulsifying agent(s) is/are present in an amount at least 2% w/w, preferably at least 5% w/w of the formulation.

23. A formulation according to any one of the preceding claims which includes at least one self-emulsifying agent selected from glyceryl mono-oleate, glyceryl monostearate and self-emulsifying grade glyceryl monostearate.

24. A formulation according to any one of claims 1 to 23 wherein the lipophilic medicament is at least one cannabis extract.

25. A formulation according to any one of claims 1 to 23 wherein the lipophilic medicament comprises one or more natural or synthetic cannabinoids.

26. A formulation according to claim 25 wherein the lipophilic medicament comprises tetrahydrocannabinol, Δ^8-tetrahydrocannabinol, Δ^9-tetrahydrocannabinol propyl analogue, cannabidiol, cannabidiol propyl analogue, cannabinol,

cannabichromene, cannabichromene propyl analogue, cannabigerol or any mixture thereof.

27. A pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, which formulation comprises at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, wherein the lipophilic medicament is at least one extract from at least one cannabis plant.

28. A pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, which formulation comprises at least one lipophilic medicament and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, wherein the lipophilic medicament comprises a combination of two or more natural or synthetic cannabinoids.

29. A formulation according to claim 28 wherein the lipophilic medicament comprises any combination of two or more cannabinoids selected from tetrahydrocannabinol, Δ^9-tetrahydrocannabinol, Δ^9-tetrahydrocannabinol propyl analogue, cannabidiol, cannabidiol propyl analogue, cannabinol, cannabichromene, cannabichromene propyl analogue and cannabigerol.

30. A pharmaceutical formulation for use in administration of a lipophilic medicament via a mucosal surface, the formulation comprising at least one lipophilic medicament, at least one solvent, at least one co-solvent and at least one self emulsifying agent, wherein upon hydration the formulation forms an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament, characterised in that the total amount of solvent and co-solvent present in the formulation is greater than 55% w/w of the formulation.

31. A formulation according to claim 30 wherein the total amount of solvent plus co-solvent present in the formulation is greater than 65% w/w, preferably greater than 70% w/w, more preferably greater than 75% w/w, more preferably greater than 80% w/w, more preferably greater than 85% w/w of the formulation.

32. A formulation according to claim 31 which comprises between 80% w/w and 95% w/w of solvent plus co-solvent.

33. A formulation according to any one of claims 30 to 32 wherein the solvent is a lower alkyl (C_1-C_4) alcohol and the co-solvent is propylene glycol, glycerol, a macrogol or a polyoxy hydrogenated castor oil.

34. A formulation according to claim 33 wherein the solvent is ethanol and the co-solvent is propylene glycol.

35. A formulation according to claim 34 wherein the ratio of ethanol to propylene glycol present in the formulation is between 4:1 and 1:4.

36. A formulation according to claim 35 wherein the ratio of ethanol to propylene glycol present in the formulation is about 1:1.

37. A formulation according to claim 33 wherein the solvent is ethanol and the co-solvent is a polyoxy hydrogenated castor oil, preferably cremophor RH40™.

38. A formulation according to claim 37 wherein the amount of polyoxy hydrogenated castor oil present in the formulation is between 5 and 55% w/w of the total amount of polyoxy hydrogenated castor oil plus ethanol present in the formulation.

39. A formulation according to claim 38 wherein the amount of polyoxy hydrogenated castor oil present in the formulation is between 20 and 40% w/w of the total amount of polyoxy hydrogenated castor oil plus ethanol present in the formulation.

40. A formulation according to claim 39 wherein the amount of polyoxy hydrogenated castor oil present in the formulation is approximately 30% w/w of the total amount of polyoxy hydrogenated castor oil plus ethanol present in the formulation.

41. A formulation according to any one of claims 30 to 40 wherein the self-emulsifying agent(s) is/are present in an amount greater than 1% w/w of the formulation.

42. A formulation according to any one of claims 30 to 41 which comprises glyceryl mono-oleate as a self-emulsifying agent.

43. A formulation according to any one of claims 30 to 42 wherein the lipophilic medicament comprises at least one cannabis extract.

44. A formulation according to any one of claims 30 to 42 wherein the lipophilic medicament comprises one or more natural or synthetic cannabinoids.

45. A formulation according to claim 44 wherein the lipophilic medicament comprises tetrahydrocannabinol, Δ^9-tetrahydrocannabinol, Δ^9-tetrahydrocannabinol propyl analogue, cannabidiol, cannabidiol propyl analogue, cannabinol, cannabichromene, cannabichromene propyl analogue, cannabigerol or any mixture thereof.

46. A cannabis-based pharmaceutical formulation which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC), or the cannabinoids, or the cannabinoids tetrahydrocannabinovarin (THCV) and cannabidivarin (CBDV), in a pre-defined ratio by weight.

47. A pharmaceutical formulation according to claim 43 which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) in approximately equal amounts by weight.

48. A pharmaceutical formulation according to

claim 43 which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC), wherein the THC is present in an amount by weight which is greater than the amount by weight of CBD.

49. A pharmaceutical formulation according to claim 43 which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC), wherein the CBD is present in an amount by weight which is greater than the amount by weight of THC.

50. A formulation according to claim 49 wherein the ratio by weight of CBD to THC is greater than 2.5:1.

51. A formulation according to claim 49 or claim 50 wherein the ratio by weight of CBD to THC is between 99:1 and 2.5:1, preferably between about 20:1 and about 2.5:1.

52. A formulation according to any one of claims 49 to 51 wherein the ratio by weight of CBD to THC is about 19:1.

53. A formulation according to any one of claims 49 to 51 wherein the ratio by weight of CBD to THC is in the range from about 5:1 to about 3:1.

54. A formulation according to any one of claims 49 to 53 which is substantially free of cannabinoids other than CBD and THC.

55. A formulation according to claim 54 which is substantially free of other cannabinoids found in

Cannabis sp.

56. A formulation according to any one of claims 49 to 55 wherein said CBD and THC are in substantially pure form.

57. A formulation according to any one of claims 49 to 53 which further comprises one or more other cannabinoids.

58. A formulation according to claim 57 wherein the one or more other cannabinoids are tetrahydrocannabinovarin (THCV) and/or cannabidivarin (CBDV).

59. A formulation according to any one of claims 49 to 53, 57 or 58 wherein the CBD and THC are derived from at least one extract from at least one Cannabis plant, said at least one extract comprising all the naturally occurring cannabinoids in said plant.

60. A formulation according to claim 59 wherein the Cannabis plant is selected from Cannabis sativa, Cannabis indica, a genetic cross between them, a self-cross or a hybrid thereof.

61. A formulation according to claim 60 wherein the Cannabis plant is Cannabis sativa, subspecies indica and is selected from var. indica and var. kafiristanica.

62. A formulation as claimed in any one of claims 59 to 61 which comprises extracts from two or

more different Cannabis varieties wherein in the final formulation the amount of CBD is greater than the amount of THC by weight.

63. A formulation according to any one of claims 59 to 61 wherein said extract is prepared by supercritical or sub-critical fluid extraction of dried Cannabis plant.

64. A method of preparing a Cannabis-based pharmaceutical formulation which comprises CBD and THC in a pre-defined ratio by weight which method comprises the steps of :

a) providing at least one dried Cannabis plant for which the amount of CBD and THC by weight is known;

b) preparing an extract of said at least one Cannabis plant

c) formulating a material from said extract or extracts prepared in step (c) which exhibits said pre-defined ratio of CBD to THC; and

d) further formulating the product of step (c) into a pharmaceutical formulation with a pharmaceutically acceptable carrier or diluent.

65. A method according to claim 64 wherein the extract of step (b) is prepared using at least one of the following procedures:

(i) maceration

71. A method according to any one of claims 64 to 70 wherein said pre-defined ratio by weight of CBD

to THC is about 19:1.

72. A method according to any one of claims 64 to 69 wherein said pre-defined ratio by weight of CBD to THC is in the range from about 5:1 to 3:1.

73. A method according to any one of claims 64 to 68 wherein the formulation comprises approximately equal amounts of CBD and THC by weight.

74. A method according to any one of claims 64 to 68 wherein the amount by weight of THC in said formulation is greater than the amount by weight of CBD.

75. A method according to any one of claims 64 to 68 wherein said pre-defined ratio by weight of CBD to THC is between 1:99 and 1:1.5.

76. A method according to any one of claims 64 to 68 wherein said pre-defined ratio by weight of CBD to THC is about 1:39.

77. A method according to any one of claims 64 to 68 wherein said pre-defined ratio by weight of CBD to THC is about 1:2.

78. A method according to any one of claims 64 to 77 wherein said formulation is formulated for delivery nasally, sub-lingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, sub-cutaneously, transdermally, intra-vaginally, intra-urethrally, by nebulizer, as inhaled vapour or by installation directly into the

bladder.

79. A method according to any one of claims 64 to 77 wherein said formulation is formulated to deliver CBD prior to delivery of THC and/or to provide a controlled release formulation.

80. A Cannabis-based pharmaceutical formulation which is obtainable by the method of any one of claims 64 to 79.

81. A pharmaceutical formulation according to claim 46 which comprises both the cannabinoids tetrahydrocannabinovarin (THCV) and cannabidivarin (CBDV) wherein the CBDV is present in an amount by weight which is greater than the amount by weight of THCV.

82. A formulation according to claim 81 which further comprises CBD and/or THC.

83. A formulation according to claim 81 or 82 wherein the ratio by weight of CBDV to THCV is greater than 1.5:1.

84. A formulation according to any one of claims 81 to 83 wherein the ratio by weight of CBDV to THCV is in the range from about 99:1 to about 1.5:1, preferably from about 20:1 to about 2.5:1.

85. A formulation according to any one of claims 81 to 84 wherein the ratio by weight of CBDV to THCV is about 9:1.

86. A formulation according to any one of claims 81 to 84 wherein the ratio of CBDV to THCV by weight is from about 5:1 to 3:1.

87. A formulation according to claim 81 or any one of claims 83 to 86 which is substantially free from other cannabinoids found in Cannabis sp.

88. A formulation according to any one of claims 81 to 87 wherein the CBDV and THCV form part of an extract from a Cannabis plant, said extract comprising all of the naturally occurring cannabinoids in said plant.

89. A formulation according to claim 88 wherein the Cannabis plant is selected from Cannabis sativa, Cannabis indica or a genetic cross between them, a self-cross or a hybrid thereof.

90. A modification of the method according to any one of claims 64 to 79 wherein in step (a) at least one dried Cannabis plant is provided for which the amount of CBDV and THCV is known and a pharmaceutical formulation is prepared comprising a pre-determined ratio by weight of CBDV to THCV instead of CBD and THC.

91. A pharmaceutical formulation which comprises both the cannabinoids THC and THCV wherein the THCV is present in an amount by weight which is approximately equal to or greater than the amount by weight of THC.

92. A pharmaceutical formulation according to claim 91 wherein the ratio by weight of THCV to THC is

between 99:1 and 1.5:1

93. A formulation according to claim 91 or 92 wherein the ratio by weight of THCV to THC is approximately 17:3.

94. A formulation according to any one of claims 91 to 93 which also comprises CBD and/or CBDV at an amount by weight which is less than the amount by weight of THCV.

95. A formulation according to any one of claims 91 to 94 wherein the THCV and THC form part of an extract from a Cannabis plant, said extract comprising all the naturally occurring cannabinoids in said plant.

96. A formulation according to claim 95 wherein said Cannabis plant is selected from Cannabis sativa, Cannabis indica or the result of a genetic cross between them, a self-cross or a hybrid thereof.

97. A modification of the method according to any one of claims 64 to 79 wherein in step (a) at least one dried cannabis plant is provided for which the amount of THCV and THC is known and a pharmaceutical formulation is prepared comprising a pre-determined ratio by weight of THCV to THC instead of CBD to THC.

98. A Cannabis-based pharmaceutical formulation which is obtainable by the method of claim 90 or claim 97.

99. A pharmaceutical formulation according to any one of claims 46 to 63, 80 to 89, 91 to 95 or 98 for use in the treatment of inflammatory disease or any disease or condition during the course of which oxidative stress plays a part.

100. A pharmaceutical formulation according to claim 53 or 86 for use in the treatment of rheumatoid arthritis, or inflammatory bowel disease or Crohn's disease..

101. A pharmaceutical formulation for use according to claim 100 wherein in the formulation the CBD and THC and/or the CBDV and THCV form part of an extract from a Cannabis plant. said extract comprising all the naturally occurring cannabinoids in said plant.

102. A pharmaceutical formulation according to claim 52 or 85 for use in the treatment of psychotic disorders, epilepsy, movement disorders, stroke, head injury, or diseases which require appetite suppression.

103. A pharmaceutical formulation for use according to claim 102 wherein in the formulation the CBD and THC and/or CBDV and THCV form part of an extract from a Cannabis plant, said extract comprising all the naturally occurring cannabinoids in said plant.

104. A pharmaceutical formulation obtainable by the method of claim 64 or 90 which comprises approximately equal amounts of CBD and THC or THCV and

CBDV for the treatment of multiple sclerosis, spinal cord injury, peripheral neuropathy or other neurogenic pain.

105. A pharmaceutical formulation which comprises a ratio by weight of THC to CBD or THCV to CBDV of from about 39:1 to about 99:1 for use in the treatment of cancer pain or migraine or for stimulation of appetite.

106. A pharmaceutical formulation for use according to claim 105 wherein the ratio by weight of THC to CBD or THCV to CBDV is approximately 39:1.

107. A pharmaceutical formulation for use according to claim 105 or 106 wherein in the formulation the THC and CBD and/or THCV and CBDV form part of an extract from a Cannabis plant , said extract comprising all the naturally occurring cannabinoids in said plant.

108. The pharmaceutical formulation of any of claims 91 to 95 for use in the treatment of cancer pain or migraine or for stimulation of the appetite.

109. Use of Cannabidiol (CBD) to extend the shelf-life of a pharmaceutical product which comprises one or more other biologically active components.

110. The use according to claim 109 wherein the biologically active component is a lipophilic substance.

111. The use according to claim 110 wherein the

biologically active molecule is selected from cannabinol (CBN), cannabigerol (CBG), THC, CBDV and THCV.

112. A pharmaceutical formulation according to any one of claims 1 to 45 which further includes the features of any one of claims 46 to 63, 80 to 89, 91 to 96 or 98.

113. A pump-action spray comprising a pharmaceutical formulation as according to any one of claims 1 to 45, 46 to 63, 80 to 89, 91 to 96 or 98.

114. A pump-action spray according to claim 113 wherein the formulation is delivered through a nozzle such that the mean aerodynamic diameter of the particles produced is between 15 and 45 microns.

FIG. 1.



FIG. 2.



FIG. 3.

FIG. 4.



FIG 5


DAD1 A, Sig=220,16 Ref=400,16 (D:\HPLCDA~1\DATA\200909\CBD00016.D)
mAU
400
300
200
100
0
CBD
THC
Example Chromatogram of CBD CBME (AC661)
0
2.5
5
7.5
10
12.5
15
17.5
20
min

FIG 6

DAD1 A, Sig=220,16 Ref=400,16 (D:\HPLCDA~1\DATA\020909\CBD00021.D)
mAU
Example Chromatogram of THC CBME (AC662)
CBD
CBN
THC
200
150
100
50
0
-50
0
2.5
5
7.5
10
12.5
15
17.5
20
min